<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1003257033
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RESPAL 2 MG TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RISPERIDONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        13.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jordan Sweden Medical and Sterilization Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 679]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-DAWAA MEDICAL SERVICES CO. LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AX08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>RESPAL belongs to a group of medicines called &lsquo;anti-psychotics&rsquo;.</p><p>&nbsp;</p><p>RESPAL is used to treat the following:</p><p>-&nbsp; Schizophrenia, where you may see, hear or feel things that are not there, believe things that are not true or feel unusually suspicious, or confused.</p><p>-&nbsp; Mania, where you may feel very excited, elated, agitated, enthusiastic or hyperactive Mania occurs in an illness called &ldquo;bipolar disorder&rdquo;.</p><p>-&nbsp; Short-term treatment (up to 6 weeks) of long-term aggression in people with Alzheimer&rsquo;s dementia, who harm themselves or others. Alternative (nondrug) treatments should have been used previously.</p><p>-&nbsp; Short-term treatment (up to 6 weeks) of long-term, aggression in intellectually disabled children (at least 5 years of age) and adolescents with conduct disorder.</p><p>&nbsp;</p><p>Risperdal can help alleviate the symptoms of your disease and stop your symptoms from coming back.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>Do not take RESPAL</u></strong></p><p>You are allergic (hypersensitive) to risperidone or any of the other ingredients of this medicine (listed in section 6).</p><p>If you are not sure if the above applies to you, talk to your doctor or pharmacist before using RESPAL.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Take special care with RESPAL</u></strong></p><p>Talk to your doctor or pharmacist before taking RESPAL if:</p><p>&bull; You have a heart problem. Examples include an irregular heart rhythm or if you are prone to low blood pressure or if you are using medicines for your blood pressure. Risperdal may cause low blood pressure. Your dose may need to be adjusted.</p><p>&bull; You know of any factors which would favour you having a stroke, such as high blood pressure, cardiovascular disorder or blood vessel problems in the brain.</p><p>&middot;&nbsp;&nbsp;&nbsp; You have ever experienced involuntary movements of the tongue, mouth and face.</p><p>&bull; You have ever had a condition whose symptoms include high temperature, muscle stiffness, sweating or a lowered level of consciousness (also known as Neuroleptic Malignant Syndrome).</p><p>&bull; You have Parkinson&rsquo;s disease or dementia.</p><p>&bull; You know that you have had low levels of white blood cells in the past (which may or may not have been caused by other medicines).</p><p>&bull; You are diabetic</p><p>&bull; You have epilepsy</p><p>&bull; You are a man and you have ever had a prolonged or painful erection</p><p>&bull; You have problems controlling your body temperature or overheating</p><p>&bull; You have kidney problems</p><p>&bull; You have liver problems</p><p>&bull; You have an abnormally high level of the hormone prolactin in your blood or if you have a possible prolactin-dependenttumour.</p><p>&bull; You or someone else in your family has a history of blood clots, as antipsychotics have been associated with formation of blood clots.</p><p>&nbsp;</p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using RESPAL.</p><p>&nbsp;</p><p>As dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood has been seen very rarely with patients taking RESPAL, your doctor may check your white blood cell counts.</p><p>&nbsp;</p><p>RESPAL may cause you to gain weight. Significant weight gain may adversely affect your health. Your doctor should regularly measure your body weight.</p><p>&nbsp;</p><p>As diabetes mellitus or worsening of pre-existing diabetes mellitus have been seen with patients taking RESPAL, your doctor should check for signs of high blood sugar. In patients with pre-existing diabetes mellitus blood glucose should be monitored regularly.</p><p>&nbsp;</p><p>During an operation on the eye for cloudiness of the lens (cataract), the pupil (the black circle in the middle of your eye) may not increase in size as needed. Also, the iris (the coloured part of the eye) may become floppy during surgery and that may lead to eye damage. If you are planning to have an operation on your eye, make sure you tell your eye doctor that you are taking this medicine.</p><p>&nbsp;</p><p><strong>Elderly people with dementia</strong></p><p>In elderly patients with dementia, there is an increased risk of stroke. You should not take risperidone if you have dementia caused by stroke.</p><p>During treatment with risperidone you should frequently see your doctor.</p><p>Medical treatment should be sought straight away if you or your care-giver notice a sudden change in your mental state or sudden weakness or numbness of your face, arms or legs, especially on one side, or slurred speech, even for a short period of time. These may be signs of a stroke.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Before treatment is started for conduct disorder, other causes of aggressive behaviour should have been ruled out.</p><p>If during treatment with risperidone tiredness occurs, a change in the time of administration might improve attention difficulties.</p><p>Before treatment is started your, or your child&rsquo;s body weight may be measured and it may be regularly monitored during treatment.</p><p>&nbsp;</p><p><strong><u>Taking other medicines</u></strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>It is especially important to talk to your doctor or pharmacist if you are taking any of the following:</strong></p><p>&bull; Medicines that work on your brain such as to help you calm down (benzodiazepines) or some medicines for pain (opiates), medicines for allergy (some antihistamines), as risperidone may increase the sedative effect of all of these.</p><p>&bull; Medicines that may change the electrical activity of your heart, such as medicines for malaria, heart rhythm problems, allergies (anti-histamines), some antidepressants or other medicines for mental problems.</p><p>&bull; Medicines that cause a slow heart beat.</p><p>&bull; Medicines that cause low blood potassium (such as certain diuretics).</p><p>&bull; Medicines to treat raised blood pressure. RESPAL can lower blood pressure.</p><p>&bull; Medicines for Parkinson&rsquo;s disease (such as levodopa).</p><p>&bull; Water tablets (diuretics) used for heart problems or swelling of parts of your body due to a buildup of too much fluid (such as furosemide or chlorothiazide). RESPAL taken by itself or with furosemide, may have an increased risk of stroke or death in elderly people with dementia.</p><p>&nbsp;</p><p><strong>The following medicines may reduce the effect of Risperidone</strong></p><p>&bull; Rifampicin (a medicine for treating some infections)</p><p>&bull; Carbamazepine, phenytoin (medicines for epilepsy)</p><p>&bull; Phenobarbital</p><p>If you start or stop taking such medicines you may need a different dose of Risperidone.</p><p><strong>&nbsp;</strong></p><p><strong>The following medicines may increase the effect of Risperidone</strong></p><p>&bull; Quinidine (used for certain types of heart disease)</p><p>&bull; Antidepressants such as paroxetine, fluoxetine, tricyclic antidepressants</p><p>&bull; Medicines known as beta blockers (used to treat high blood pressure)</p><p>&bull; Phenothiazines (such as medicines used to treat psychosis or to calm down)</p><p>&bull; Cimetidine, ranitidine (blockers of the acidity of stomach)</p><p>&nbsp;</p><p>If you start or stop taking such medicines you may need a different dose of Risperidone.</p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using RESPAL.</p><p>&nbsp;</p><p><strong><u>Taking RESPAL with food and drink</u></strong></p><p>You can take this medicine with or without food.</p><p>You should avoid drinking alcohol when taking RESPAL.</p><p><strong>&nbsp;</strong></p><p><strong><u>Pregnancy and breast-feeding</u></strong></p><p>&bull; If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor will decide if you can take it.</p><p>&bull; The following symptoms may occur in newborn babies, of mothers that have used RESPAL in the last trimester (last three months of their pregnancy): shaking, muscle stiffness, and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.</p><p>&bull; RESPAL can raise your levels of a hormone called &ldquo;prolactin&rdquo; that may impact fertility (see Possible side effects).</p><p>&nbsp;</p><p><strong><u>Driving and using machines</u></strong></p><p>Dizziness, tiredness, and vision problems may occur during treatment with RESPAL. Do not drive or use any tools or machines without talking to your doctor first.</p><p>&nbsp;</p><p><strong><u>Important information about some of the ingredients of RESPAL</u></strong></p><p>None.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>&nbsp;</strong></p><p><strong>The recommended dose is as follows:</strong></p><p><strong>For the treatment of schizophrenia:</strong></p><p><strong>Adults</strong></p><p>&bull; The usual starting dose is 2 mg per day, this may be increased to 4 mg per day on the second day.</p><p>&bull; Your dose may then be adjusted by your doctor depending on how you respond to the treatment.</p><p>&bull; Most people feel better with daily doses of 4 to 6 mg.</p><p>&bull; This total daily dose can be divided into either one or two doses a day. Your doctor will tell you which is the best for you.</p><p><strong>Elderly people</strong></p><p>&bull; Your starting dose will normally be 0.5 mg twice a day.</p><p>&bull; Your dose may then be gradually increased by your doctor to 1 mg to 2 mg twice a day.</p><p>&bull; Your doctor will tell you which is the best for you.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>For the treatment of mania:</strong></p><p><strong>Adults</strong></p><p>&bull; Your starting dose will usually be 2 mg once a day</p><p>&bull; Your dose may then be gradually adjusted by your doctor depending on how you respond to the treatment</p><p>&bull; Most people feel better with doses of 1 to 6 mg once a day.</p><p><strong>Elderly people</strong></p><p>&bull; Your starting dose will usually be 0.5 mg twice a day</p><p>&bull; Your dose may then be gradually adjusted by your doctor to 1 mg to 2 mg twice a day depending on how much you respond to the treatment.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>For the treatment of long-standing aggression in people with Alzheimer&rsquo;s dementia:</strong></p><p><strong>Adults (including elderly people)</strong></p><p>&bull; Your starting dose will normally be 0.25 mg twice a day</p><p>&bull; Your dose may then be gradually adjusted by your doctor depending on how you respond to the treatment</p><p>&bull; Most people feel better with 0.5 mg twice a day. Some patients may need 1 mg twice a day</p><p>&bull; Treatment duration in patients with Alzheimer&rsquo;s dementia should be not more than 6 weeks.</p><p><strong>Use in children and adolescents</strong></p><p>&bull; Children and adolescents under 18 years old should not be treated with RESPAL for schizophrenia or mania.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>For the treatment of conduct disorder:</strong></p><p>The dose will depend on your child&rsquo;s weight:</p><p><strong>For children who weigh less than 50 kg</strong></p><p>&bull; The starting dose will normally be 0.25 mg once a day</p><p>&bull; The dose may be increased every other day in steps of 0.25 mg per day.</p><p>&bull; The usual maintenance dose is 0.25 mg to 0.75 mg once a day.</p><p><strong>For children who weigh 50 kg or more</strong></p><p>&bull; The starting dose will normally be 0.5 mg once a day</p><p>&bull; The dose may be increased every other day in steps of 0.5 mg per day.</p><p>&bull; The usual maintenance dose is 0.5 mg to 1.5 mg once a day.</p><p>&nbsp;</p><p>Treatment duration in patients with conduct disorder should be not more than 6 weeks.</p><p>&nbsp;</p><p>Children under 5 years old should not be treated with Risperdal for conduct disorder.</p><p><strong>&nbsp;</strong></p><p><strong>People with kidney or liver problems:</strong></p><p>Regardless of the disease to be treated, all starting doses and following doses of risperidone should be halved. Dose increases should be slower in these patients.</p><p>Risperidone should be used with caution in this patient group.</p><p><strong>&nbsp;</strong></p><p><strong><u>If you take more RESPAL than you should</u></strong></p><p>&bull; See a doctor right away. Take the medicine pack with you.</p><p>&bull; In case of overdose you may feel sleepy or tired, or have abnormal body movements, problems standing and walking,&nbsp; feel dizzy due to low blood pressure, or have abnormal heartbeats or fits.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>If you forget to take RESPAL</u></strong></p><p>&bull; If you forget to take a dose, take it as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose and continue as usual. If you miss two or more doses, contact your doctor.</p><p>&bull; Do not take a double dose (two doses at the same time) to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong><u>If you stop taking RESPAL</u></strong></p><p>You should not stop taking this medicine unless told to do so by your doctor. Your symptoms may return. If your doctor decides to stop this medicine, your dose may be decreased gradually over a few days.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>If you have any further questions on the use of this product, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Tell your doctor immediately if you:</strong></p><p>Experience blood clots in the veins, especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty breathing. If you notice any if these symptoms seek medical advice immediately.</p><p>&bull; Have dementia and experience a sudden change in your mental state or sudden weakness or numbness of your face, arms or legs, especially on one side, or slurred speech, even for a short period of time. These may be signs of a stroke.</p><p>&bull; Experience fever, muscle stiffness, sweating or a lowered level of consciousness (a disorder called &ldquo;Neuroleptic Malignant Syndrome&rdquo;). Immediate medical treatment may be needed.</p><p>&bull; Are a man and experience prolonged or painful erection. This is called priapism. Immediate medical treatment may be needed.</p><p>&bull; Experience involuntary rhythmic movements of the tongue, mouth and face. Withdrawal of risperidone may be needed.</p><p>&bull; Experience severe allergic reaction characterised by fever, swollen mouth, face, lip or tongue, shortness of breath, itching, skin rash or drop in blood pressure.</p><p>&nbsp;</p><p><strong>The following side effects may happen:</strong></p><p><strong>Very Common (affects more than 1 user in 10):</strong></p><p>&bull; Difficulty falling or staying asleep.</p><p>&bull; Parkinsonism: This condition may include: slow or impaired movement, sensation of stiffness or tightness of the muscles (making your movements jerky), and sometimes even a sensation of movement &ldquo;freezing up&rdquo; and then restarting. Other signs of parkinsonism include a slow shuffling walk, a tremor while at rest, increased saliva and/or drooling, and a loss of expression on the face.</p><p>&bull; Feeling sleepy, or less alert.</p><p>&bull; Headache.</p><p>&nbsp;</p><p><strong>Common (affects 1 to 10 users in 100):</strong></p><p>&bull; Pneumonia, Infection of the chest (bronchitis), Common cold symptoms, Sinus infection Urinary tract infection Ear infection, Feeling like you have the flu.</p><p>&bull; Risperdal can raise your levels of a hormone called &ldquo;prolactin&rdquo; found on a blood test (which may or may not cause symptoms). When symptoms of high prolactin occur, they may include in men breast swelling, difficulty in getting or maintaining erections, or other sexual dysfunction. In women they may include breast discomfort, leakage of</p><p>milk from the breasts, missed menstrual periods, or other problems with your cycle.</p><p>&bull; Weight gain, Increased appetite, Decreased appetite.</p><p>&bull; Sleep disorder, Irritability, Depression, Anxiety, Restlessness.</p><p>&bull; Dystonia: This is a condition involving slow or sustained involuntary contraction of muscles. While it can involve any part of the body (and may result in abnormal posture), dystonia often involves muscles of the face, including abnormal movements of the eyes, mouth, tongue or jaw.</p><p>&bull; Dizziness.</p><p>&bull; Dyskinesia: This is a condition involving involuntary muscle movements, and can include repetitive, spastic or writhing movements, or twitching.</p><p>&bull; Tremor (shaking).</p><p>&bull; Blurry vision, Eye infection or &ldquo;pink eye&rdquo;.</p><p>&bull; Rapid heart rate, High blood pressure, Shortness of breath.</p><p>&bull; Sore throat, Cough, Nosebleeds, Stuff y nose.</p><p>&bull; Abdominal pain, Abdominal discomfort, Vomiting, Nausea, Constipation, Diarrhea, Indigestion, Dry mouth, Toothache.</p><p>&bull; Rash, Skin redness.</p><p>&bull; Muscle spasms, Bone or muscle ache, Back pain, Joint pain.</p><p>&bull; Incontinence (lack of control) of urine.</p><p>&bull; Swelling of the body, arms or legs, Fever, Chest pain, Weakness, Fatigue (tiredness), Pain.</p><p>&bull; Fall.</p><p>&nbsp;</p><p><strong>Uncommon (affects 1 to 10 users in 1000):</strong></p><p>&bull; Infection of the breathing passages, Bladder infection, &lsquo;Eye infection, Tonsillitis, Fungal infection of the nails, Infection of the skin, An infection confined to a single area of skin or part of the body, Viral infection, Skin inflammation caused by mites.</p><p>&bull; Decrease in the type of white blood cells that help to protect you against infection, White blood cell count decreased Decrease in platelets (blood cells that help you stop bleeding), Anemia, Decrease in red blood cells, Increase in eosinophils (a type of white blood cell) in your blood.</p><p>&bull; Allergic reaction.</p><p>&bull; Diabetes or worsening of diabetes, High blood sugar, Excessive drinking of water.</p><p>&bull; Weight loss, Loss of appetite resulting in malnutrition and low body weight.</p><p>&bull; Increased cholesterol in your blood.</p><p>&bull; Elated mood (mania), Confusion, Decreased sexual drive, Nervousness, Nightmares.</p><p>&bull; Tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body). Tell your doctor immediately if you experience involuntary rhythmic movements of the tongue, mouth and face. Withdrawal of Risperdal may be needed.</p><p>&bull; Sudden loss of blood supply to brain (stroke or &ldquo;mini&rdquo; stroke).</p><p>&bull; Unresponsive to stimuli, Loss of consciousness, Low level of consciousness.</p><p>&bull; Convulsion (fits), Fainting.</p><p>&bull; A restless urge to move parts of your body, Balance disorder, Abnormal coordination, Dizziness upon standing, Disturbance in attention, Problems with speech, Loss or abnormal sense of taste, Reduced sensation of skin to pain and touch, A sensation of tingling, pricking, or numbness skin.</p><p>&bull; Oversensitivity of the eyes to light, Dry eye, Increased tears, Redness of the eyes.</p><p>&bull; Sensation of spinning (vertigo), Ringing in the .ears, Ear pain</p><p>&bull; Atrial fibrillation (an abnormal heart rhythm), An interruption in conduction between the upper and lower parts of the heart, Abnormal electrical conduction of the heart, Prolongation of the QT interval from your heart, Slow heart rate, Abnormal electrical tracing of the heart (electrocardiogram or ECG), A fl uttering or pounding feeling in your chest (palpitations).</p><p>&bull; Low blood pressure, Low blood pressure upon standing (consequently, some people taking Risperdal may feel faint, dizzy, or may pass out when they stand up or sit up suddenly, Flushing.</p><p>&bull; Pneumonia caused by inhaling food, Lung congestion, Congestion of breathing passages, Crackly lung sounds, Wheezing, Voice disorder, Breathing passage disorder.</p><p>&bull; Stomach or intestinal infection, Stool incontinence, Very hard stool, Difficulty swallowing, Excessive passing of gas or win.</p><p>&bull; Hives (or &ldquo;nettle rash&rdquo;), Itching, Hair loss, Thickening of skin, Eczema, Dry skin, Skin discoloration, Acne, Flaky, itchy scalp or skin, Skin disorder, Skin lesion.</p><p>&bull; An increase of CPK (creatine phosphokinase) in your blood, an enzyme which is sometimes released with muscle breakdown.</p><p>&bull; Abnormal posture, Joint stiffness, Joint swelling, Muscle weakness, Neck pain.</p><p>&bull; Frequent passing of urine, Inability to pass urine, Pain when passing urine.</p><p>&bull; Erectile dysfunction, Ejaculation disorder.</p><p>&bull; Loss of menstrual periods, Missed menstrual periods or other problems with your cycle (females).</p><p>&bull; Development of breasts in men, Leakage of milk from the breasts, Sexual dysfunction, Breast pain, Breast discomfort, Vaginal discharge.</p><p>&bull; Swelling of the face, mouth, eyes, or lips.</p><p>&bull; Chills, An increase in body temperature.</p><p>&bull; A change in the way you walk.</p><p>&bull; Feeling thirsty, Feeling unwell, Chest discomfort, Feeling &ldquo;out of sorts&rdquo;, Discomfort.</p><p>&bull; Increased liver transaminases in your blood, Increased GGT (a liver enzyme called gamma-glutamyltransferase) in your blood, Increased liver enzymes in your blood.</p><p>&bull; Procedural pain.</p><p><strong>&nbsp;</strong></p><p><strong>Rare (affects 1 to 10 users in 10,000):</strong></p><p>&bull; Infection.</p><p>&bull; Inappropriate secretion of a hormone that controls urine volume.</p><p>&bull; Sugar in the urine, Low blood sugar, High blood triglycerides (a fat).</p><p>&bull; Lack of emotion, Inability to reach orgasm.</p><p>&bull; Neuroleptic malignant syndrome (confusion, reduced or loss of consciousness, high fever, and severe muscle stiff ness).</p><p>&bull; Blood vessel problems in the brain.</p><p>&bull; Coma due to uncontrolled diabetes.</p><p>&bull; Shaking of the head.</p><p>&bull; Glaucoma (increased pressure within the eyeball), Problems with movement of your eyes, Eye rolling, Eyelid margin crusting.</p><p>&bull; Eye problems during cataract surgery. During cataract surgery, a condition called intraoperative floppy iris syndrome (IFIS) can happen if you. take or have taken Risperdal. If you need to have cataract surgery, be sure to tell your eye doctor if you take or have taken this medicine.</p><p>&bull; Dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood.</p><p>&bull; Severe allergic reaction characterised by fever, swollen mouth, face, lip or tongue, shortness of breath, itching, skin rash and sometimes drop in blood pressure.</p><p>&bull; Dangerously excessive intake of water.</p><p>&bull; Irregular heart beat.</p><p>&bull; Blood clot in the legs, Blood clot in the lungs.</p><p>&bull; Trouble breathing during sleep (sleep apnea), Fast, shallow breathing.</p><p>&bull; Inflammation of the pancreas, A blockage in the bowels.</p><p>&bull; Swollen tongue, Chapped lips, Rash on skin related to drug.</p><p>&bull; Dandruff.</p><p>&bull; Breakdown of muscle fibers and pain in muscles (rhabdomyolysis).</p><p>&bull; A delay in menstrual periods, Enlargement of the glands in your breasts, Breast enlargement, Discharge from the breasts.</p><p>&bull; Increased insulin (a hormone that controls blood sugar levels) in your blood.</p><p>&bull; Priapism (a prolonged penile erection that may require surgical treatment).</p><p>&bull; Hardening of the skin.</p><p>&bull; Decreased body temperature, A decrease in body temperature, Coldness in arms and legs.</p><p>&bull; Symptoms of drug withdrawal.</p><p>&bull; Yellowing of the skin and the eyes (jaundice).</p><p><strong>&nbsp;</strong></p><p><strong>Very rare (affects less than 1 user in 10,000):</strong></p><p>&bull; Life threatening complications of uncontrolled diabetes.</p><p>&bull; Serious allergic reaction with swelling that may involve the throat and lead to difficulty breathing.</p><p>&bull; Lack of bowel muscle movement that causes blockage.</p><p>&nbsp;</p><p>The following side effect has been seen with the use of another medicine called paliperidone that is very similar to risperidone, so these can also be expected with RESPAL: Rapid heartbeat upon standing.</p><p><strong>&nbsp;</strong></p><p><strong>Additional side effects in children and adolescents</strong></p><p>In general, side effects in children are expected to be similar to those in adults.</p><p>The following side effects were reported more often in children and adolescents (5 to 17 years) than in adults: feeling sleepy, or less alert, fatigue (tiredness), headache, increased appetite, vomiting, common cold symptoms, nasal congestion, abdominal pain, dizziness, cough, fever, tremor (shaking), diarrhoea, and incontinence (lack of control) of urine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep out of the reach and sight of children.</p><p>- Do not use RESPAL after the expiry date which is stated on the carton and blister after EXP.</p><p>- Do not use any RESPAL pack that is damaged or shows signs of tampering.</p><p>- Store below 30<sup>o</sup>C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>RESPAL 1 </strong>contains 1mg of Risperidone.</p><p><strong>RESPAL 2 </strong>contains 2mg of Risperidone.</p><p><strong>RESPAL 4 </strong>contains 4mg of Risperidone.</p><p>The other ingredients are: Lactose Monohydrate, Microcrystalline Cellulose, Sodium Lauryl Sulphate, Colloidal Silicon Dioxide, Maize Starch, Magnesium Stearate, HPMC 5CP, Glycerin, PEG, Talc.</p><p>Respal 2: also contains Sunset yellow&nbsp;&nbsp;</p><p>Respal 4: also contains FD &amp; C Blue and Quinoline yellow</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pharmaceutical form: Tablet.

Pack size: 20 Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jordan Sweden Medical and Sterilization Company (Joswe-medical)</p><p>P.O. Box 851831 Amman 11185 Jordan</p><p>E-mail: joswe@go.com.jo</p><p>www.joswe.com</p><p>Tel: +962 6 5859765, +962 6 5728327</p><p>Fax: +962 6 5814526, +962 6 5728326</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 01/2023; Revision number R3.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ريسبال</strong> ينتمي إلى مجموعة من الأدوية تسمى &quot;مضادات الذهان&quot;.</p><p dir="RTL">&nbsp;يستخدم <strong>ريسبال</strong> لعلاج ما يلي :</p><p dir="RTL">- الفصام، حيث يمكن رؤية، سماع أو الشعور بأشياء غير موجودة، والإعتقاد بأشياء ليست صحيحة أو التشكيك بشكل غير عادي أو التشتت.</p><p dir="RTL">- الهوس، حيث الشعور بالانفعال الشديد، الإعجاب، الغضب، الحماس أو فرط النشاط. يظهر الهوس في مرض يسمى &quot;الإضطراب ثنائي القطب&quot;.</p><p dir="RTL">- العلاج قصير الأجل (لمدة تصل إلى 6 أسابيع) لمرضى الزهايمر-الخرف المصابين بالسلوك العدواني طويل الأمد، الذين قد يلحقون الضرر بأنفسهم أو بغيرهم. كما ينبغي أن يكون قد تم استخدام العلاجات البديلة (غير الأدوية) سابقا̋.</p><p dir="RTL">- العلاج قصير الأجل (لمدة تصل إلى 6 أسابيع) للأطفال المعاقين ذهنيا المصابين بالسلوك العدواني طويل الأمد ( لا يقل العمر عن 5 سنوات) والمراهقين الذين يعانون من اضطراب السلوك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يساعد <strong>ريسبال</strong> على تخفيف وعدم عودة أعراض المرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>لا تتناول </u></strong><strong><u>ريسبال</u></strong></p><p dir="RTL">إذا كنت تعاني من الحساسية لرسبريدون أو لأي مكونات أخرى في هذا الدواء (راجع فقرة &quot;معلومات إضافية&quot;)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp; إذا لم تكن متأكدا بأن ما ذكر أعلاه ينطبق عليك أم لا، قم باستشارة طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>التحذيرات و الاحتياطات</u></strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول<strong> ريسبال</strong> إذا:</p><p dir="RTL">&bull; لديك مشكلة في القلب. مثل عدم انتظام ضربات القلب أو إذا كنت عرضة لانخفاض ضغط الدم أو إذا كنت تستخدم أدوية لخفض ضغط الدم. <strong>ريسبال</strong> قد يسبب انخفاض ضغط الدم، لذا قد تحتاج إلى تعديل الجرعة.</p><p dir="RTL">&bull; كنت تعرف أن لديك أي من العوامل التي تزيد احتمالية حدوث السكتة الدماغية، مثل ارتفاع ضغط الدم، واضطرابات الأوعية الدموية القلبية أو مشاكل الأوعية الدموية في الدماغ.</p><p dir="RTL">&bull; حدث لك في أي وقت مضى حركات لا إرادية في اللسان والفم والوجه.</p><p dir="RTL">&bull; كان لديك حالة مرضية والتي أعراضها تشمل ارتفاع درجة الحرارة، تصلب العضلات، والتعرق أو تدني مستوى الوعي (المعروف أيضا باسم متلازمة الذهان الخبيثة).</p><p dir="RTL">&bull; لديك مرض باركنسون أو الخرف.</p><p dir="RTL">&bull; كنت تعلم أنه كان لديك سابقا مستويات منخفضة من خلايا الدم البيضاء (والتي قد تكون أو لا تكون ناجمة عن الأدوية الأخرى).</p><p dir="RTL">&bull; لديك سكري.</p><p dir="RTL">&bull; لديك صرع.</p><p dir="RTL">&bull; كنت رجل وكان لديك في أي وقت مضى انتصاب لفترة طويلة أو مؤلم.</p><p dir="RTL">&bull; لديك مشاكل في السيطرة على درجة حرارة الجسم أو ارتفاع درجة الحرارة.</p><p dir="RTL">&bull; لديك مشاكل في الكلى.</p><p dir="RTL">&bull; لديك مشاكل في الكبد.</p><p dir="RTL">&bull; كان لديك مستوى عال بشكل غير طبيعي من هرمون البرولاكتين في الدم أو إذا كان لديك الورم المعتمد على البرولاكتين.</p><p dir="RTL">&bull; كان لديك أنت أو أي شخص آخر في عائلتك تاريخ حدوث جلطات دموية، حيث ارتبطت مضادات الذهان مع تشكل جلطات الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكن متأكدا بأن ما ذكر أعلاه ينطبق عليك أم لا، قم باستشارة طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بشكل خطير أرقام منخفضة من نوع معين من خلايا الدم البيضاء اللازمة لمكافحة العدوى في الدم قد شوهد بشكل &nbsp;نادرا جدا مع المرضى الذين يتناولون ريسبال، لذا فإن طبيبك قد يتحقق من تعداد الكريات البيض الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ريسبال قد يسبب زيادة الوزن. زيادة الوزن بشكل ملحوظ قد تؤثر سلبا على صحتك. يجب على طبيبك أن يراقب بانتظام وزن الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حدث داء السكري أو تفاقم مرض السكري في المرضى الذين يتناولون ريسبال، يجب أن يتحقق طبيبك من وجود علامات على ارتفاع السكر في الدم. في المرضى الذين يعانون من السكري يجب قياس مستوى الجلوكوز في الدم بانتظام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">خلال العمليات الجراحية لاعتمام العدسة، فان البؤبؤ (الدائرة السوداء في منتصف العين) قد لا يزيد حجمه حسب الحاجة. أيضا، القزحية (الجزء الملون من العين) قد تصبح مرنة أثناء الجراحة والذي قد يؤدي إلى ضرر في العين. إذا كنت تخطط لعملية جراحية في العين، أخبر طبيب العيون بأنك تأخذ هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كبار السن الذين يعانون من الخرف</strong></p><p dir="RTL">في المرضى المسنين المصابين بالخرف، هناك خطر متزايد من السكتة الدماغية. لذا، يجب أن لا تأخذ رسبيريدون إذا كان الخرف لديك ناجم عن السكتة الدماغية.</p><p dir="RTL">خلال فترة العلاج برسبيريدون يجب عليك مراجعة الطبيب بشكل مستمر.</p><p dir="RTL">إذا لاحظت أنت أو الشخص الذي يقوم على رعايتك حدوث تغيير مفاجئ في الحالة العقلية أو ضعف مفاجئ أو خدر في وجهك والذراعين أو الساقين، وخاصة إذا كانت في جانب واحد، أوكلام متداخل، ولو لفترة قصيرة من الوقت. لأنه قد تكون هذه علامات سكتة الدماغية .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">قبل البدء بعلاج اضطرابات السلوك يجب استبعاد الأسباب الأخرى التي تسبب السلوك العدواني.</p><p dir="RTL">إذا كان هناك شعور بالتعب أثناء العلاج برسبيريدون، ان التغيير في وقت تناول الدواء قد يؤدي إلى تحسين صعوبات الانتباه.</p><p dir="RTL">قبل البدء بالعلاج يجب قياس وزن الجسم و يجب متابعته بشكل منتظم خلال العلاج.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>تناول أدوية أخرى</u></strong></p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا̋ أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>من الضروري اخبار الطبيب أو الصيدلي خصوصا̋ اذا كنت تتناول أي من الأدوية التالية:</strong></p><p dir="RTL">&bull; الأدوية التي تعمل على الدماغ لمساعدتك على التهدئة (البنزوديازيبين) أو بعض الأدوية المخففة للألم (المواد الأفيونية)، وأدوية معالجة الحساسية (مضادات الهيستامين)، وذلك لأن الرسبيريدون قد يزيد من التأثير المهدىء لهذه الأدوية.</p><p dir="RTL">&bull; الأدوية التي يمكن أن تغير النشاط الكهربائي للقلب، مثل أدوية مكافحة الملاريا، وأدوية معالجة مشاكل ضربات القلب، وأدوية الحساسية (مضادات الهيستامين)، وبعض مضادات الاكتئاب وغيرها من الأدوية المستخدمة لعلاج المشاكل العقلية.</p><p dir="RTL">&bull; الأدوية التي تسبب بطء ضربات القلب.</p><p dir="RTL">&bull; الأدوية التي تسبب انخفاض البوتاسيوم في الدم (مثل بعض مدرات البول).</p><p dir="RTL">&bull; الأدوية المستخدمة لعلاج ارتفاع ضغط الدم. ريسبال قد يخفض ضغط الدم.</p><p dir="RTL">&bull; الأدوية المستخدمة لعلاج مرض الباركنسون (مثل ليفودوبا).</p><p dir="RTL">&bull; أقراص المياه (مدرات البول) تستخدم لمعالجة مشاكل القلب أو تورم أجزاء من الجسم نتيجة لتراكم الكثير من السوائل (مثل فوروسيميد أو الكلوروثيازيد). ريسبال لوحده أو مع فوروسيميد، قد يزيد مخاطر الإصابة بالسكتة الدماغية أو الموت في كبار السن الذين يعانون من الخرف.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية التالية قد تقلل من تأثير رسبيريدون</strong><br />&bull; ريفامبيسين (دواء لعلاج بعض الالتهابات).<br />&bull; كاربامازيبين، فينيتوين (أدوية لعلاج الصرع).<br />&bull; الفينوباربيتال.<br />قد تحتاج إلى تعديل جرعة الرسبيريدون إذا كنت بدأت أو توقفت عن تناول هذه الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية التالية قد تزيد من تأثير رسبيريدون</strong><br />&bull; كينيدين (دواء يستخدم لأنواع معينة من أمراض القلب).<br />&bull; مضادات الاكتئاب مثل باروكسيتين، فلوكستين، ومضادات الاكتئاب ثلاثية الحلقات.<br />&bull; الأدوية المعروفة باسم حاصرات بيتا (أدوية تستخدم لعلاج ارتفاع ضغط الدم).<br />&bull; الفينوثيازين (أدوية تستخدم لعلاج الذهان أو للتهدئة).<br />&bull; سيميتيدين، رانيتيدين (لعلاج حموضة المعدة).</p><p dir="RTL"><br />قد تحتاج إلى تعديل جرعة الرسبيريدون إذا كنت بدأت أو توقفت عن تناول هذه الأدوية.<br />إذا لم تكن متأكدا بأن ما ذكر أعلاه ينطبق عليك أم لا، قم باستشارة طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>تناول ريسبال مع الطعام والشراب </u></strong></p><p dir="RTL">يمكنك أن تتناول ريسبال مع أو بدون الطعام.</p><p dir="RTL">يجب تجنب تناول الكحول عند استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>الحمل والإرضاع</u></strong></p><p dir="RTL">&bull; اسألي طبيبك إذا كنت حاملا أو مرضعة أو&nbsp; تعتقدين أنك حامل أو تخططين للإنجاب قبل استخدام هذا الدواء. سيقرر الطبيب فيما اذا كنت تستطعين استخدام هذا الدواء.</p><p dir="RTL">&bull; قد تحدث الأعراض التالية في الأطفال حديثي الولادة للأمهات اللواتي استخدمنا ريسبال في الثلث الأخير من الحمل (الشهورالثلاثة الأخيرة من الحمل): الاهتزاز، وتصلب العضلات، و/أو ضعف، والنعاس، والإثارة، ومشاكل في التنفس، وصعوبة في الرضاعة . إذا كان طفلك يعاني من أي هذه الأعراض عندها يجب الاتصال بطبيبك.<br />&bull; قد يؤدي استخدام ريسبال إلى ارتفاع مستويات هرمون يدعى &quot;البرولاكتين&quot; الذي يؤثر على الخصوبة (راجع الآثار الجانبية المحتملة).</p><p dir="RTL"><strong><u>القيادة وتشغيل الآلات</u></strong><u> </u></p><p dir="RTL">أثناء العلاج بريسبال قد تحدث دوخة، وتعب، ومشاكل في الرؤية لذا لا تقود أو تستخدم أي أدوات أو آلات دون التحدث مع طبيبك أولا̋.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>معلومات هامة عن بعض مكونات </u></strong><strong><u>ريسبال</u></strong><strong> &nbsp;</strong><br />اتصل بالطبيب قبل تناول هذا الدواء إذا كان قد قيل لك &nbsp;من قبل الطبيب أنك لا تتحمل بعض السكريات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائماً تناول دوائك كما أخبرك الطبيب أو الصيدلاني.&nbsp; إذا لم تكن متأكداً، &nbsp;قم باستشارة طبيبك أو الصيدلاني.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الموصى بها هي على النحو التالي:</strong><br /><strong>علاج الفصام:</strong><br /><u>البالغين</u><br />&bull; الجرعة المعتادة للبدء هي 2 ملغ يوميا̋، يمكن زيادة هذه الجرعة في اليوم الثاني إلى 4 ملغم في اليوم الواحد.<br />&bull; يمكن بعد ذلك تعديل الجرعة الخاصة بك عن طريق طبيبك حسب استجابتك للعلاج.<br />&bull; معظم الناس ترتاح لتناول جرعات يومية من 4 إلى 6 ملغم.<br />&bull; يمكن تقسيم هذه الجرعة اليومية إلى جرعة واحدة أو جرعتين في اليوم. طبيبك سوف يحدد ما هو الأفضل بالنسبة لك.<br /><u>كبار السن</u><br />&bull; الجرعة المعتادة للبدء هي 0.5 ملغم مرتين في اليوم.<br />&bull; يمكن بعد ذلك زيادة الجرعه الخاصة بك تدريجيا من قبل الطبيب من 1 ملغم إلى 2 ملغم مرتين في اليوم.<br />&bull; طبيبك سوف يحدد ما هو الأفضل بالنسبة لك.</p><p dir="RTL"><br /><strong><u>علاج الهوس:</u></strong><br /><u>البالغين</u><br />&bull; الجرعة المعتادة للبدء هي 2 ملغم مرة واحدة يوميا̋.<br />&bull; يمكن بعد ذلك تعديل الجرعة الخاصة بك عن طريق طبيبك حسب استجابتك للعلاج.<br />&bull; معظم الناس ترتاح لتناول جرعات يومية من 1-6 ملغم مرة واحدة يوميا̋.<br /><u>كبار السن</u><br />&bull; الجرعة المعتادة للبدء هي 0.5 ملغم مرتين في اليوم.<br />&bull; يمكن بعد ذلك زيادة الجرعه الخاصة بك تدريجيا من قبل الطبيب من 1 ملغم إلى 2 ملغم مرتين في اليوم حسب استجابتك للعلاج.</p><p>&nbsp;</p><p dir="RTL"><strong>علاج مرضى الزهايمر-الخرف المصابين بالسلوك العدواني طويل الأمد:</strong><br /><u>البالغين (بما في ذلك كبار السن)</u><br />&bull; الجرعة المعتادة للبدء هي 0.25 ملغم مرتين في اليوم.<br />&bull; &nbsp;يمكن بعد ذلك تعديل الجرعة الخاصة بك عن طريق طبيبك حسب استجابتك للعلاج.<br />&bull; معظم الناس ترتاح لتناول جرعات يومية 0.5 ملغم مرتين في اليوم. بعض المرضى قد يحتاجون لجرعة 1 ملغم مرتين في اليوم.<br />&bull; يجب أن لا تكون مدة العلاج في المرضى الذين يعانون من الزهايمر-الخرف أكثر من 6 أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><br /><strong>استخدام في الأطفال والمراهقين</strong><br />&bull; لا يجوز معالجة الأطفال والمراهقين دون سن 18 عاما المصابين بالفصام أو الهوس بريسبال.</p><p dir="RTL"><br /><strong>علاج اضطرابات السلوك:</strong><br />سوف تعتمد الجرعة على وزن طفلك:<br /><u>وزن الأطفال أقل من 50 كجم</u><br />&bull; الجرعة المعتادة للبدء هي 0.25 ملغم مرة واحدة يوميا̋.<br />&bull; يمكن زيادة الجرعة تدريجيا يوم بعد يوم &nbsp;0.25 ملغم يوميا̋.<br />&bull; الجرعة المعتادة للاستمرار هي من &nbsp;0.25 ملغم إلى 0.75 ملغم مرة واحدة يوميا̋.<br /><u>وزن الأطفال 50 كجم أو أكثر</u><br />&bull; الجرعة المعتادة للبدء هي 0.5 ملغ مرة واحدة يوميا̋.<br />&bull; يمكن زيادة الجرعة تدريجيا يوم بعد يوم 0.5 ملغم يوميا̋.<br />&bull; الجرعة المعتادة للاستمرار هي من 0.5 ملغم إلى 1.5 ملغم مرة واحدة يوميا̋.<br />وينبغي أن لا تكون مدة العلاج في المرضى الذين يعانون من اضطرابات السلوك أكثر من 6 أسابيع.<br />الأطفال دون سن 5 سنوات من العمر يجب ألا يعالجوا بريسبال لاضطراب السلوك.</p><p dir="RTL"><u>الأشخاص الذين يعانون من مشاكل في الكلى أو الكبد:</u><br />بغض النظر عن المرض الذي يتم علاجه يجب تناول نصف الجرعة المعتادة ويكون تعديل الجرعة بشكل أبطأ في هؤلاء المرضى.<br />وينبغي أن يستخدم رسبيريدون بحذر في هذه المجموعة من المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>إذا</u></strong><strong><u> </u></strong><strong><u>تناولت</u></strong><strong><u> </u></strong><strong><u>أقراص</u></strong><strong><u> </u></strong><strong><u>ريسبال </u></strong><strong><u>&nbsp;</u></strong><strong><u>أكثر</u></strong><strong><u> </u></strong><strong><u>مما</u></strong><strong><u> </u></strong><strong><u>يجب</u></strong></p><p dir="RTL">&bull; راجع الطبيب على الفور وخذ عبوة الدواء معك.<br />&bull; في حال الجرعة الزائدة قد تشعر بالنعاس أو التعب، أو قد يكون لديك حركات غير طبيعية، ومشاكل الوقوف والمشي، والشعور بالدوار بسبب انخفاض ضغط الدم، أو دقات قلب غير طبيعية أو نوبات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>إذا</u></strong><strong><u> </u></strong><strong><u>نسيت</u></strong><strong><u> </u></strong><strong><u>تناول</u></strong><strong><u> </u></strong><strong><u>جرعة</u></strong><strong><u> </u></strong><strong><u>ريسبال &nbsp;</u></strong></p><p dir="RTL">إذا نسيت تناول الجرعة تناولها حال تذكرك لها، عموماً، لا تتناول الجرعة التي نسيتها إذا اقترب موعد الجرعة التالية. اتصل بطبيبك، اذا نسيت تناول جرعتين أو أكثر. لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>إذا</u></strong><strong><u> </u></strong><strong><u>توقفت</u></strong><strong><u> </u></strong><strong><u>عن</u></strong><strong><u> </u></strong><strong><u>تناول</u></strong><strong><u> </u></strong><strong><u>أقراص</u></strong><strong><u> </u></strong><strong><u>ريسبال &nbsp;</u></strong></p><p dir="RTL">يجب أن لا تتوقف عن تناول هذا الدواء إلا إذا طلب الطبيب. وذلك لأنه قد ترجع الأعراض الخاصة بك. إذا قرر الطبيب وقف هذا الدواء، قد يتم تخفيض الجرعة تدريجيا على مدى بضعة أيام. إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>كان</strong><strong> </strong><strong>لديك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>أسئلة</strong><strong> </strong><strong>اضافية</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>هذا الدواء،</strong><strong> </strong><strong>قم</strong><strong> </strong><strong>باستشارة</strong><strong> </strong><strong>الطبيب أو</strong><strong> </strong><strong>الصيدلاني</strong><strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب آثارا جانبية على الرغم من عدم حدوثها لدى الجميع.<br /><strong>أخبر طبيبك فورا إذا كنت:</strong><br />تعاني من جلطات في الأوردة وخصوصا في الساقين (وتشمل الاعراض تورم، وألم، واحمرار الساق)، وهذه الجلطات قد تنتقل عبر الأوعية الدموية إلى الرئتين مما يسبب آلام في الصدر وصعوبة في التنفس. إذا لاحظت أي من هذه الأعراض، راجع الطبيب فورا.<br />&bull; تعاني من الخرف ولاحظت حدوث تغيير مفاجئ في الحالة العقلية أو ضعف مفاجئ أو خدر في وجهك والذراعين أو الساقين، وخاصة إذا كانت في جانب واحد، أوكلام متداخل، ولو لفترة قصيرة من الوقت. لأنه قد تكون هذه علامات سكتة الدماغية.</p><p dir="RTL">&bull; تعاني من الحمى، تصلب العضلات، والتعرق أو مستوى منخفض من الوعي (اضطراب يسمى &quot;متلازمة مضادات الذهان الخبيثة&quot;)، قد تكون هناك حاجة إلى العلاج الطبي الفوري.<br />&bull; رجل و تعرضت لانتصاب طويل ومؤلم (قساح)، قد تكون هناك حاجة إلى العلاج الطبي الفوري.<br />&bull; تعاني من حركات غير إرادية في اللسان والفم والوجه، &nbsp;قد تكون هناك حاجة الى التوقف عن تناول رسبيريدون.<br />&bull; تعاني من رد فعل تحسسي يتميز بالحمى وتورم الفم والوجه والشفاه أو اللسان، وضيق في التنفس، والحكة، الطفح الجلدي أو انخفاض في ضغط الدم.</p><p dir="RTL"><br /><strong>قد تحدث الآثار الجانبية التالية:<br />شائعة جدا̋ (</strong><strong>تؤثر على أكثر من 1 من كل&nbsp; 10 مستخدمين</strong><strong>):</strong><br />&bull; صعوبة في النوم أو البقاء نائما̋.<br />&bull; باركنسون/الرعاش: ويمكن أن تشمل هذه الحالة: ضعف أو بطء الحركة، والإحساس بتصلب أو ضيق في العضلات (جعل الحركات مهزوزة)، وأحيانا الاحساس بتجمد الحركة ، ومن ثم إعادة القدرة على الحركة. وتشمل علامات الرعاش الاخرى البطء في المشي ، هزة عند الراحة، وزيادة اللعاب و/ أو الترويل، وفقدان التعبير على الوجه.<br />&bull; الشعور بالنعاس وأقل تأهبا.<br />&bull; الصداع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (</strong><strong>تؤثر على 1 إلى 10 من كل 100 مستخدم</strong><strong>):</strong><br />&bull; الالتهاب الرئوي والصدر (التهاب الشعب الهوائية)، وأعراض نزلات البرد، التهاب الجيوب الأنفية، التهاب المسالك البولية، عدوى الأذن، والشعور وكأنه لديك انفلونزا.<br />&bull; ريسبال قد يسببارتفاع مستوى هرمون يدعى &quot;البرولاكتين&quot; في فحص الدم (والتي قد تسبب أو لا تسبب أعراض). عندما تحدث أعراض ارتفاع البرولاكتين، فإنها تتضمن الاعراض التالية في الرجال تورم الثدي، وصعوبة في حدوث أو الحفاظ على الانتصاب، أو عجز الجنسي. أما في النساء فإنها قد تشمل عدم الراحة في الثدي، وتسرب الحليب من الثديين، وغياب الدورة الشهرية، أو مشاكل أخرى مع الدورة الشهرية.<br />&bull; زيادة الوزن، زيادة الشهية، وانخفاض الشهية.<br />&bull; اضطراب النوم، والتهيج، والاكتئاب، والقلق، وعدم الراحة.<br />&bull; خلل التوتر العضلي: هذه حالة تتضمن انكماش للعضلات غير أرادي بشكل بطيئ أو مستمر. مع أنه قد تكون هذه الحالة في &nbsp;أي جزء من الجسم (ويمكن أن يؤدي الى وقفة غير طبيعية)، الا أن خلل التوتر غالبا ما يحدث في عضلات الوجه، بما في ذلك حركات غير طبيعية للعينين والفم واللسان أو الفك.<br />&bull; دوخة.<br />&bull; خلل الحركة: هذا هي حالة تتضمن حركات لاإرادية للعضلات، ويمكن أن تشمل الحركات المتكررة، المتشنجة أو المتلوية، أو الوخز.<br />&bull; الهزة/الرجفة.<br />&bull; ضبابية الرؤية، وعدوى العين أو &quot;العين الوردية&quot;.<br />&bull; سرعة دقات القلب، وارتفاع ضغط الدم، وضيق في التنفس.<br />&bull; التهاب الحلق، السعال، نزيف الأنف.<br />&bull; ألم وعدم راحة في البطن ، التقيؤ، الغثيان، الإمساك، الإسهال، عسر الهضم، جفاف الفم، وجع الأسنان.<br />&bull; الطفح الجلدي، احمرار الجلد.<br />&bull; تشنجات العضلات، آلام العظام أو العضلات ، آلام الظهر، آلام المفاصل.<br />&bull; سلس البول (عدم التحكم).<br />&bull; تورم الجسم والذراعين أو الساقين، حمى، ألم في الصدر، الضعف، التعب، الألم.<br />&bull; السقوط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong><strong>) </strong><strong>تؤثر على 1 إلى 10 من كل 1000 مستخدم</strong><strong>:(</strong></p><p dir="RTL">&bull; التهاب القصبات، التهاب المثانة، التهاب العين، التهاب اللوزتين، العدوى الفطرية للأظافر، عدوى الجلد، وعدوى محصورة في منطقة واحدة من الجلد أو جزء من الجسم، والعدوى الفيروسية، والتهاب الجلد الناجم عن العث.<br />&bull; انخفاض خلايا الدم البيضاء التي تساعد في حمايتك ضد العدوى، وانخفاض عدد خلايا الدم البيضاء، انخفاض في الصفائح الدموية (خلايا الدم التي تساعد على إيقاف النزيف)، فقر الدم، وانخفاض في خلايا الدم الحمراء، وزيادة في الحمضات (وهو نوع من خلايا الدم البيضاء) في دمك.<br />&bull; رد فعل تحسسي.<br />&bull; مرض السكري أو تفاقم مرض السكري، وارتفاع جلوكوز الدم والشرب المفرط للماء.<br />&bull; فقدان الوزن، فقدان الشهية مما يؤدي إلى سوء التغذية وانخفاض وزن الجسم.<br />&bull; زيادة نسبة الكوليسترول في الدم.<br />&bull; مزاج مبتهج (الهوس)، والارتباك، وانخفاض الدافع الجنسي، والعصبية، والكوابيس.<br />&bull; خلل الحركة المتأخر (الوخز أو رجيج الحركات التي لا يمكنك التحكم فيها في وجهك، واللسان، أو أجزاء أخرى من الجسم). أخبر طبيبك فورا إذا حدث معك حركات إيقاعية غير أرادية في اللسان والفم والوجه. قد تكون هناك حاجةالى وقف ريسبال.<br />&bull; التوقف المفاجىء لتدفق الدم إلى الدماغ (السكتة الدماغية أو سكتة دماغية مصغرة).<br />&bull; عدم الاستجابة للمحفزات، فقدان الوعي، ومستوى منخفض من الوعي.<br />&bull; التشنج (نوبات)، الإغماء.<br />&bull; رغبة في تحريك أجزاء من الجسم، واضطراب التوازن، الدوخة عند الوقوف، واضطراب في الانتباه، ومشاكل في الكلام، وفقدان أو شعور غير طبيعي للطعم، وانخفاض إحساس الجلد بالألم واللمس، والإحساس بالوخز، الشكة، أو خدران الجلد.<br />&bull; حساسية عين مفرطة للضوء، وجفاف العين، زيادة الدموع، احمرار في العينين.<br />&bull; الإحساس بالدوار، الرنين في الأذن، وألم الأذن.<br />&bull; الرجفان الأذيني (إيقاع غير طبيعي للقلب)، انقطاع في التوصيل بين الجزأين العلوي والسفلي للقلب، توصيل كهربائي غير طبيعي للقلب وإطالة أمد الفترة الفاصلة QT من قلبك، وبطء معدل ضربات القلب ، تتبع كهربائي غير طبيعي للقلب (ECG)، وخفقان الصدر.<br />&bull; انخفاض ضغط الدم، وانخفاض ضغط الدم عند الوقوف (وبالتالي، فإن بعض الأشخاص الذين يتناولون ريسبال قد يشعرون بالدوار، أو تورد الوجه.<br />&bull; الالتهاب الرئوي الناجم عن استنشاق المواد الغذائية، واحتقان الرئة، واحتقان ممرات التنفس، أصوات طقطقة في الرئة ، وصفير، اضطراب الصوت، اضطراب ممرات التنفس.<br />&bull; التهاب المعدة أو الأمعاء، سلس البراز، البراز الصلب جدا، صعوبة في البلع، فرط &nbsp;اخراج الغازات.<br />&bull; شرى (أو &quot;طفح القراص&quot;)، والحكة، وفقدان الشعر، سماكة الجلد، والأكزيما، والجلد الجاف، اختلاف لون الجلد، حب الشباب، حكة في فروة الرأس أو الجلد، اضطرابات الجلد، وآفة الجلد.<br />&bull; زيادة مستوى الكرياتين فسفوكيناز في الدم، وهو الانزيم الذي يفرز عند انهيار العضلات.<br />&bull; وقفة غير طبيعية، وتصلب المفاصل، تورم المفاصل، ضعف العضلات، وآلام الرقبة.<br />&bull; بول متكرر، وعدم القدرة على التبول، ألم عند التبول.<br />&bull; عدم القدرة على الانتصاب، واضطراب القذف.<br />&bull; انقطاع الطمث أو مشاكل أخرى مع دورتك (للإناث).<br />&bull; نمو الثدي في الرجال، تسرب الحليب من الثديين، والخلل الوظيفي الجنسي، ألم الثدي، وعدم الراحة الثدي، افرازات مهبلية.<br />&bull; تورم في الوجه والفم والعينين، أو الشفاه.<br />&bull; قشعريرة، زيادة في درجة حرارة الجسم.<br />&bull; تغير في طريقة المشي.<br />&bull; الشعور بالعطش، والشعور بالإعياء، وعدم الراحة في الصدر، وعدم الراحة.<br />&bull; زيادة ترانساميناسات الكبد في الدم، وزيادة انزيم الكبد ناقل الغاما-غلوتاميل في الدم، زيادة إنزيمات الكبد في الدم.<br />&bull; ألم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة (تؤثر على 1 إلى 10 من كل 10000 مستخدم):</strong></p><p dir="RTL">&bull; العدوى.<br />&bull; إفراز غير صحيح للهرمون الذي يتحكم في حجم البول.<br />&bull; السكر في البول، وانخفاض نسبة السكر في الدم وارتفاع الدهون الثلاثية في الدم (الدهون).<br />&bull; عدم وجود العاطفة، عدم القدرة على الوصول إلى النشوة الجنسية.<br />&bull; متلازمة مضادات الذهان الخبيثة (الارتباك، وانخفاض أو فقدان الوعي، وارتفاع في درجة الحرارة، وتصلب شديد في العضلات).<br />&bull; مشاكل في الأوعية الدموية الدماغية.<br />&bull; غيبوبة بسبب مرض السكري الغير منضبط.<br />&bull; هز الرأس.<br />&bull; الجلوكوما (ارتفاع الضغط داخل مقلة العين)، مشاكل مع حركة عينيك، وتداول العين، تقشر هامش الجفن.<br />&bull; مشاكل في العين خلال جراحة اعتمام العدسة. أثناء جراحة اعتمام العدسة ، تحدث حالة متلازمة القزحية المرنة أثناء العملية (IFIS) إذا كنت تتناول &nbsp;أو تناولت ريسبال. إذا كنت بحاجة إلى جراحة اعتمام العدسة، عليك اعلام طبيب العيونانك تتناول أو تناولت ريسبال.<br />&bull; انخفاض بشكل خطير لنوع معين من خلايا الدم البيضاء اللازمة لمكافحة العدوى في الدم.<br />&bull; رد فعل تحسسي شديد يتميز بالحمى وتورم الفم والوجه والشفاه أو اللسان، وضيق في التنفس، والحكة، الطفح الجلدي و أحيانا انخفاض في ضغط الدم.<br />&bull; الإفراط في تناول الماء بشكل خطير.<br />&bull; عدم انتظام ضربات القلب.<br />&bull; جلطة الدم في الساقين وجلطة الدم في الرئتين.<br />&bull; صعوبة في التنفس أثناء النوم (توقف التنفس أثناء النوم)، والتنفس الضحل.<br />&bull; التهاب البنكرياس، وانسداد في الأمعاء.<br />&bull; تورم اللسان، تشقق الشفتين، طفح على الجلد.<br />&bull; قشرة الرأس.<br />&bull; انحلال ألياف العضلات وآلام في العضلات (انحلال الربيدات).<br />&bull; تأخير في الدورة الشهرية، تضخم الغدد في الثدي، تضخم الثدي، إفرازات من الثدي.<br />&bull; ارتفاع مستوى الأنسولين في الدم (الهرمون الذي يتحكم في مستويات السكر في الدم).<br />&bull; القساح ( انتصاب القضيب لفترة طويلة الذي قد يتطلب العلاج الجراحي).<br />&bull; تصلب الجلد.<br />&bull; انخفاض درجة حرارة الجسم، برودة في الذراعين والساقين.<br />&bull; أعراض انسحاب الدواء.<br />&bull; اصفرار الجلد والعينين (اليرقان).</p><p dir="RTL">&nbsp;</p><p><strong>نادرة جدا̋ (تؤثر على أقل من 1&nbsp; من كل 10000 مستخدم):</strong><br />&bull;&nbsp; مضاعفات مرض السكري الغير منضبط التي تهدد الحياة.<br />&bull; رد فعل تحسسي خطير مع تورم في الحلق، والذي يؤدي إلى صعوبة في التنفس.<br />&bull; عدم حركة العضلات التي تسبب انسداد الأمعاء.<br /><br />يمكن توقع الآثار الجانبية التالية مع رسبريدون حيث أنها حثت عند استخدام دواء آخر يسمى الباليبيريدون وهو دواء مشابه جدا لرسبيريدون: سرعة ضربات القلب عند الوقوف.<br /><br /><strong>آثار جانبية إضافية في الأطفال والمراهقين</strong><br />الآثار جانبية عند الأطفال من المتوقع أن تكون مشابهة لتلك الموجودة في البالغين بشكل عام.<br />تم الإبلاغ عن الآثار الجانبية التالية في أكثر الأحيان في الأطفال والمراهقين (5 إلى 17 سنة) أكثر من البالغين: الشعور بالنعاس، أو أقل تأهب، والاجهاد (التعب)، والصداع، وزيادة الشهية، والقيء، وأعراض نزلات البرد واحتقان الأنف، وألم في البطن ، والدوخة، والسعال، والحمى، ورعاش (الاهتزاز)، والإسهال، وسلس البول (عدم التحكم).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- يحفظ بعيدا عن متناول الأطفال.</p><p>- لا تستخدم <strong>ريسبال &nbsp;</strong>بعد انتهاء فترة الصلاحية&nbsp; المذكورة على اللاصق الداخلي و العبوة الخارجية.</p><p>- لا تستخدم <strong>ريسبال </strong>عند ملاحظة أي علامة تلف فيه.</p><p>- يخزن في درجة حرارة أقل من 30 درجة مئوية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ريسبال</strong><strong> </strong><strong>1</strong> &nbsp;يحتوي على 1 ملغم رسبريدون.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ريسبال</strong><strong> </strong><strong>2</strong> &nbsp;يحتوي على 2 ملغم رسبريدون.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ريسبال</strong><strong> </strong><strong>4</strong> &nbsp;يحتوي على 4 ملغم رسبريدون.</p><p>&nbsp;</p><p>المكونات الأخرى هي: لاكتوز، ميكروكريستالين السليولوز، بوفيدون، كروس بوفيدون، كبريتات لوريل الصوديوم، ثاني أكسيد السيليكون الغروي، نشا، مغنيسيوم ستيرات، هيدروكسي بروبيل ميثيل سيليلوز 5CP، جليسيرين، بولي ايثيلين جلايكول، تالك.</p><p>ريسبال 2: يحتوي أيضاً على صبغة لون أصفر (Sunset yellow)</p><p>، ريسبال 4: يحتوي أيضاً على صبغة لون أزرق رقم 2 و كينولين أصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشكل الصيدلاني: أقراص.</p><p dir="RTL">حجم العبوة: 20 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة الأردنية السويدية للمنتجات الطبية و التعقيم.</p><p dir="RTL">صندوق بريد 851831&nbsp; عمان 11185 &nbsp;الأردن</p><p dir="RTL">الايميل: joswe@go.com.jo</p><p dir="RTL">www.joswe.com</p><p dir="RTL">هاتف: +962 6 5859765 ، +962 6 5728327</p><p dir="RTL">فاكس: +962 6 5814526، +962 6 5728326</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في 01/2023 ؛ رقم المراجعة R3.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Respal® 2 Tablets 
Respal® 4 Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Respal 2: Each tablet contains 2 mg Risperidone.
Respal 4: Each tablet contains 4 mg Risperidone.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets
Respal 2: Light orange to orange caplet, embossed with Res 2 and bisected from one side and trisected from the other side.
Respal 4: Light green to green caplet, embossed with Respal 4 from one side and bisected from the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RESPAL is indicated for the treatment of schizophrenia.</p><p>RESPAL is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorders.</p><p>RESPAL is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer&#39;s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others.</p><p>RESPAL is indicated for the short-term symptomatic treatment (up to 6 weeks) of persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation diagnosed according to DSM-IV criteria, in whom the severity of aggressive or other disruptive behaviours require pharmacologic treatment. Pharmacological treatment should be an integral part of a more comprehensive treatment programme, including psychosocial and educational intervention. It is recommended that Risperidone be prescribed by a specialist in child neurology and child and adolescent psychiatry or physicians well familiar with the treatment of conduct disorder of children and adolescents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>Schizophrenia</p><p>Adults</p><p>RESPAL may be given once daily or twice daily.</p><p>Patients should start with 2 mg/day Risperidone. The dosage may be increased on the second day to 4 mg. Subsequently, the dosage can be maintained unchanged, or further individualised, if needed. Most patients will benefit from daily doses between 4 and 6 mg. In some patients, a slower titration phase and a lower starting and maintenance dose may be appropriate.</p><p>Doses above 10 mg/day have not demonstrated superior efficacy to lower doses and may cause increased incidence of extrapyramidal symptoms. Safety of doses above 16 mg/day has not been evaluated, and are therefore not recommended.</p><p>Elderly</p><p>A starting dose of 0.5 mg twice daily is recommended. This dosage can be individually adjusted with 0.5 mg twice daily increments to 1 to 2 mg twice daily.</p><p>Paediatric population</p><p>Risperidone is not recommended for use in children below age 18 with schizophrenia due to a lack of data on efficacy.</p><p>Manic episodes in bipolar disorder</p><p>Adults</p><p>RESPAL should be administered on a once daily schedule, starting with 2 mg Risperidone. Dosage adjustments, if indicated, should occur at intervals of not less than 24 hours and in dosage increments of 1 mg per day. Risperidone can be administered in flexible doses over a range of 1 to 6 mg per day to optimise each patient&#39;s level of efficacy and tolerability. Daily doses over 6 mg Risperidone have not been investigated in patients with manic episodes.</p><p>As with all symptomatic treatments, the continued use of RESPAL must be evaluated and justified on an ongoing basis.</p><p>Elderly</p><p>A starting dose of 0.5 mg twice daily is recommended. This dosage can be individually adjusted with 0.5 mg twice daily increments to 1 to 2 mg twice daily. Since clinical experience in elderly is limited, caution should be exercised.</p><p>Paediatric population</p><p>Risperidone is not recommended for use in children below age 18 with bipolar mania due to a lack of data on efficacy.</p><p>Persistent aggression in patients with moderate to severe Alzheimer&#39;s dementia</p><p>A starting dose of 0.25 mg of oral solution twice daily is recommended. The oral solution is the recommended pharmaceutical form to administer 0.25 mg. This dosage can be individually adjusted by increments of 0.25 mg twice daily, not more frequently than every other day, if needed. The optimum dose is 0.5 mg twice daily for most patients. Some patients, however, may benefit from doses up to 1 mg twice daily.</p><p>RESPAL should not be used more than 6 weeks in patients with persistent aggression in Alzheimer&#39;s dementia. During treatment, patients must be evaluated frequently and regularly, and the need for continuing treatment reassessed.</p><p>Conduct disorder</p><p>Children and adolescents from 5 to 18 years of age</p><p>For subjects &ge; 50 kg, a starting dose of 0.5 mg once daily is recommended. This dosage can be individually adjusted by increments of 0.5 mg once daily not more frequently than every other day, if needed. The optimum dose is 1 mg once daily for most patients. Some patients, however, may benefit from 0.5 mg once daily while others may require 1.5 mg once daily. For subjects &lt; 50 kg, a starting dose of 0.25 mg of oral solution once daily is recommended. The oral solution is the recommended pharmaceutical form to administer 0.25 mg. This dosage can be individually adjusted by increments of 0.25 mg once daily not more frequently than every other day, if needed. The optimum dose is 0.5 mg once daily for most patients. Some patients, however, may benefit from 0.25 mg once daily while others may require 0.75 mg of oral solution once daily. The oral solution is the recommended pharmaceutical form to administer 0.75 mg.</p><p>As with all symptomatic treatments, the continued use of RESPAL must be evaluated and justified on an ongoing basis.</p><p>RESPAL is not recommended in children less than 5 years of age, as there is no experience in children less than 5 years of age with this disorder.</p><p>Renal and hepatic impairment</p><p>Patients with renal impairment have less ability to eliminate the active antipsychotic fraction than in adults with normal renal function. Patients with impaired hepatic function have increases in plasma concentration of the free fraction of Risperidone.</p><p>Irrespective of the indication, starting and consecutive dosing should be halved, and dose titration should be slower for patients with renal or hepatic impairment.</p><p>RESPAL should be used with caution in these groups of patients.</p><p>Method of administration</p><p>RESPAL is for oral use. Food does not affect the absorption of RESPAL.</p><p>Upon discontinuation, gradual withdrawal is advised. Acute withdrawal symptoms, including nausea, vomiting, sweating, and insomnia have very rarely been described after abrupt cessation of high doses of antipsychotic medicines (see section 4.8). Recurrence of psychotic symptoms may also occur, and the emergence of involuntary movement disorders (such as akathisia, dystonia and dyskinesia) has been reported.</p><p>Switching from other antipsychotics</p><p>When medically appropriate, gradual discontinuation of the previous treatment while RESPAL therapy is initiated is recommended. Also, if medically appropriate, when switching patients from depot antipsychotics, initiate RESPAL therapy in place of the next scheduled injection. The need for continuing existing anti-Parkinson medicines should be re-evaluated periodically.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Elderly patients with dementia</p><p>Increased mortality in elderly people with dementia</p><p>In a meta-analysis of 17 controlled trials of atypical antipsychotics, including RESPAL, elderly patients with dementia treated with atypical antipsychotics have an increased mortality compared to placebo. In placebo-controlled trials with oral RESPAL in this population, the incidence of mortality was 4.0% for RESPAL-treated patients compared to 3.1% for placebo-treated patients. The odds ratio (95% exact confidence interval) was 1.21 (0.7; 2.1). The mean age (range) of patients who died was 86 years (range 67-100). Data from two large observational studies showed that elderly people with dementia who are treated with conventional antipsychotics are also at a small increased risk of death compared with those who are not treated. There are insufficient data to give a firm estimate of the precise magnitude of the risk and the cause of the increased risk is not known. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.</p><p>Concomitant use with furosemide</p><p>In the RESPAL placebo-controlled trials in elderly patients with dementia, a higher incidence of mortality was observed in patients treated with furosemide plus Risperidone (7.3%; mean age 89 years, range 75-97) when compared to patients treated with Risperidone alone (3.1%; mean age 84 years, range 70-96) or furosemide alone (4.1%; mean age 80 years, range 67-90). The increase in mortality in patients treated with furosemide plus Risperidone was observed in two of the four clinical trials. Concomitant use of Risperidone with other diuretics (mainly thiazide diuretics used in low dose) was not associated with similar findings.</p><p>No pathophysiological mechanism has been identified to explain this finding, and no consistent pattern for cause of death observed. Nevertheless, caution should be exercised and the risks and benefits of this combination or co-treatment with other potent diuretics should be considered prior to the decision to use. There was no increased incidence of mortality among patients taking other diuretics as concomitant treatment with Risperidone. Irrespective of treatment, dehydration was an overall risk factor for mortality and should therefore be carefully avoided in elderly patients with dementia.</p><p>Cerebrovascular adverse events (CVAE)</p><p>An approximately 3-fold increased risk of cerebrovascular adverse events have been seen in randomised placebo-controlled clinical trials in the dementia population with some atypical antipsychotics. The pooled data from six placebo-controlled studies with RESPAL in mainly elderly patients (&gt; 65 years of age) with dementia showed that CVAEs (serious and non-serious, combined) occurred in 3.3% (33/1,009) of patients treated with Risperidone and 1.2% (8/712) of patients treated with placebo. The odds ratio (95% exact confidence interval) was 2.96 (1.34; 7.50). The mechanism for this increased risk is not known.</p><p>An increased risk cannot be excluded for other antipsychotics or other patient populations. RESPAL should be used with caution in patients with risk factors for stroke.</p><p>The risk of CVAEs was significantly higher in patients with mixed or vascular type of dementia when compared to Alzheimer&#39;s dementia. Therefore, patients with other types of dementias than Alzheimer&#39;s should not be treated with Risperidone.</p><p>Physicians are advised to assess the risks and benefits of the use of RESPAL in elderly patients with dementia, taking into account risk predictors for stroke in the individual patient. Patients/caregivers should be cautioned to immediately report signs and symptoms of potential CVAEs such as sudden weakness or numbness in the face, arms or legs, and speech or vision problems. All treatment options should be considered without delay, including discontinuation of Risperidone.</p><p>RESPAL should only be used short term for persistent aggression in patients with moderate to severe Alzheimer&#39;s dementia to supplement non-pharmacological approaches which have had limited or no efficacy and when there is potential risk of harm to self or others.</p><p>Patients should be reassessed regularly, and the need for continuing treatment reassessed.</p><p>Orthostatic hypotension</p><p>Due to the alpha-blocking activity of Risperidone, (orthostatic) hypotension can occur, especially during the initial dose-titration period. Clinically significant hypotension has been observed post-marketing with concomitant use of Risperidone and antihypertensive treatment. RESPAL should be used with caution in patients with known cardiovascular disease (e.g., heart failure, myocardial infarction, conduction abnormalities, dehydration, hypovolaemia, or cerebrovascular disease), and the dosage should be gradually titrated as recommended (see section 4.2). A dose reduction should be considered if hypotension occurs.</p><p>Leucopenia, neutropenia, and agranulocytosis</p><p>Events of leucopenia, neutropenia and agranulocytosis have been reported with antipsychotic agents, including RESPAL. Agranulocytosis has been reported very rarely (&lt; 1/10,000 patients) during post-marketing surveillance.</p><p>Patients with a history of a clinically significant low white blood cell count (WBC) or a drug-induced leucopenia/neutropenia should be monitored during the first few months of therapy and discontinuation of RESPAL should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.</p><p>Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count &lt; 1 &times; 109/L) should discontinue RESPAL and have their WBC followed until recovery.</p><p>Tardive dyskinesia/extrapyramidal symptoms (TD/EPS)</p><p>Medicines with dopamine receptor antagonistic properties have been associated with the induction of tardive dyskinesia characterised by rhythmical involuntary movements, predominantly of the tongue and/or face. The onset of extrapyramidal symptoms is a risk factor for tardive dyskinesia. If signs and symptoms of tardive dyskinesia appear, the discontinuation of all antipsychotics should be considered.</p><p>Caution is warranted in patients receiving both psychostimulants (e.g. methylphenidate) and Risperidone concomitantly, as extrapyramidal symptoms could emerge when adjusting one or both medications. Gradual withdrawal of stimulant treatment is recommended (see section 4.5).</p><p>Neuroleptic malignant syndrome (NMS)</p><p>Neuroleptic Malignant Syndrome, characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness and elevated serum creatine phosphokinase levels has been reported to occur with antipsychotics. Additional signs may include myoglobinuria (rhabdomyolysis) and acute renal failure. In this event, all antipsychotics, including RESPAL, should be discontinued.</p><p>Parkinson&#39;s disease and dementia with Lewy bodies</p><p>Physicians should weigh the risks versus the benefits when prescribing antipsychotics, including RESPAL, to patients with Parkinson&#39;s Disease or Dementia with Lewy Bodies (DLB). Parkinson&#39;s Disease may worsen with Risperidone. Both groups may be at increased risk of Neuroleptic Malignant Syndrome as well as having an increased sensitivity to antipsychotic medicinal products; these patients were excluded from clinical trials. Manifestation of this increased sensitivity can include confusion, obtundation, postural instability with frequent falls, in addition to extrapyramidal symptoms.</p><p>Hyperglycaemia and diabetes mellitus</p><p>Hyperglycaemia, diabetes mellitus, and exacerbation of pre-existing diabetes have been reported during treatment with RESPAL. In some cases, a prior increase in body weight has been reported which may be a predisposing factor. Association with ketoacidosis has been reported very rarely and rarely with diabetic coma. Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines. Patients treated with any atypical antipsychotic, including RESPAL, should be monitored for symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus should be monitored regularly for worsening of glucose control.</p><p>Weight gain</p><p>Significant weight gain has been reported with Risperidone use. Weight should be monitored regularly.</p><p>Hyperprolactinaemia</p><p>Hyperprolactinaemia is a common side effect of treatment with RESPAL. Evaluation of the prolactin plasma level is recommended in patients with evidence of possible prolactin-related side effects (e.g., gynaecomastia, menstrual disorders, anovulation, fertility disorder, decreased libido, erectile dysfunction, and galactorrhoea).</p><p>Tissue culture studies suggest that cell growth in human breast tumours may be stimulated by prolactin. Although no clear association with the administration of antipsychotics has so far been demonstrated in clinical and epidemiological studies, caution is recommended in patients with relevant medical history.</p><p>RESPAL should be used with caution in patients with pre-existing hyperprolactinaemia and in patients with possible prolactin-dependent tumours.</p><p>QT prolongation</p><p>QT prolongation has very rarely been reported post-marketing. As with other antipsychotics, caution should be exercised when Risperidone is prescribed in patients with known cardiovascular disease, family history of QT prolongation, bradycardia, or electrolyte disturbances (hypokalaemia, hypomagnesaemia), as it may increase the risk of arrhythmogenic effects, and in concomitant use with medicines known to prolong the QT interval.</p><p>Seizures</p><p>RESPAL should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold.</p><p>Priapism</p><p>Priapism may occur with RESPAL treatment due to its alpha-adrenergic blocking effects.</p><p>Body temperature regulation</p><p>Disruption of the body&#39;s ability to reduce core body temperature has been attributed to antipsychotic medicines. Appropriate care is advised when prescribing RESPAL to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant treatment with anticholinergic activity, or being subject to dehydration.</p><p>Antiemetic effect</p><p>An antiemetic effect was observed in preclinical studies with Risperidone. This effect, if it occurs in humans, may mask the signs and symptoms of overdosage with certain medicines or of conditions such as intestinal obstruction, Reye&#39;s syndrome, and brain tumour.</p><p>Renal and hepatic impairment</p><p>Patients with renal impairment have less ability to eliminate the active antipsychotic fraction than adults with normal renal function. Patients with impaired hepatic function have increases in plasma concentration of the free fraction of Risperidone (see section 4.2).</p><p>Venous thromboembolism</p><p>Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with RESPAL and preventative measures undertaken.</p><p>Intraoperative floppy iris syndrome</p><p>Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in patients treated with medicines with alpha1a-adrenergic antagonist effect, including RESPAL (see section 4.8).</p><p>IFIS may increase the risk of eye complications during and after the operation. Current or past use of medicines with alpha1a-adrenergic antagonist effect should be made known to the ophthalmic surgeon in advance of surgery. The potential benefit of stopping alpha1-blocking therapy prior to cataract surgery has not been established and must be weighed against the risk of stopping the antipsychotic therapy.</p><p>Paediatric population</p><p>Before Risperidone is prescribed to a child or adolescent with conduct disorder they should be fully assessed for physical and social causes of the aggressive behaviour such as pain or inappropriate environmental demands.</p><p>The sedative effect of Risperidone should be closely monitored in this population because of possible consequences on learning ability. A change in the time of administration of Risperidone could improve the impact of the sedation on attention faculties of children and adolescents.</p><p>Risperidone was associated with mean increases in body weight and body mass index (BMI). Baseline weight measurement prior to treatment and regular weight monitoring are recommended. Changes in height in the long-term open-label extension studies were within expected age-appropriate norms. The effect of long-term Risperidone treatment on sexual maturation and height has not been adequately studied.</p><p>Because of the potential effects of prolonged hyperprolactinaemia on growth and sexual maturation in children and adolescents, regular clinical evaluation of endocrinological status should be considered, including measurements of height, weight, sexual maturation, monitoring of menstrual functioning, and other potential prolactin-related effects.</p><p>Results from a small post-marketing observational study showed that Risperidone-exposed subjects between the ages of 8-16 years were on average approximately 3.0 to 4.8 cm taller than those who received other atypical antipsychotic medications. This study was not adequate to determine whether exposure to Risperidone had any impact on final adult height, or whether the result was due to a direct effect of Risperidone on bone growth, or the effect of the underlying disease itself on bone growth, or the result of better control of the underlying disease with resulting increase in linear growth.</p><p>During treatment with Risperidone regular examination for extrapyramidal symptoms and other movement disorders should also be conducted.</p><p>For specific posology recommendations in children and adolescents see section 4.2.</p><p>Excipients<br />The tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacodynamic-related interactions</p><p>Drugs known to prolong the QT interval</p><p>As with other antipsychotics, caution is advised when prescribing Risperidone with medicinal products known to prolong the QT interval, such as antiarrhythmics (e.g., quinidine, dysopiramide, procainamide, propafenone, amiodarone, sotalol), tricyclic antidepressants (i.e., amitriptyline), tetracyclic antidepressants (i.e., maprotiline), some antihistamines, other antipsychotics, some antimalarials (i.e., quinine and mefloquine), and with medicines causing electrolyte imbalance (hypokalaemia, hypomagnesaemia), bradycardia, or those which inhibit the hepatic metabolism of Risperidone. This list is indicative and not exhaustive.</p><p>Centrally-acting drugs and alcohol</p><p>Risperidone should be used with caution in combination with other centrally-acting substances notably including alcohol, opiates, antihistamines and benzodiazepines due to the increased risk of sedation.</p><p>Levodopa and dopamine agonists</p><p>RESPAL may antagonise the effect of levodopa and other dopamine agonists. If this combination is deemed necessary, particularly in end-stage Parkinson&#39;s disease, the lowest effective dose of each treatment should be prescribed.</p><p>Drugs with hypotensive effect</p><p>Clinically significant hypotension has been observed post-marketing with concomitant use of Risperidone and antihypertensive treatment.</p><p>Psychostimulants</p><p>The combined use of psychostimulants (e.g. methylphenidate) with Risperidone can lead to extrapyramidal symptoms upon change of either or both treatments (see section 4.4).</p><p>Paliperidone</p><p>Concomitant use of oral RISPERDAL with paliperidone is not recommended as paliperidone is the active metabolite of Risperidone and the combination of the two may lead to additive active antipsychotic fraction exposure.</p><p>Pharmacokinetic-related interactions</p><p>Food does not affect the absorption of RESPAL</p><p>Risperidone is mainly metabolised through CYP2D6, and to a lesser extent through CYP3A4. Both Risperidone and its active metabolite 9-hydroxy-risperidone are substrates of P-glycoprotein (P-gp).</p><p>Substances that modify CYP2D6 activity, or substances strongly inhibiting or inducing CYP3A4 and/or P-gp activity, may influence the pharmacokinetics of the Risperidone active antipsychotic fraction.</p><p>Strong CYP2D6 inhibitors</p><p>Co-administration of RISPERDAL with a strong CYP2D6 inhibitor may increase the plasma concentrations of Risperidone, but less so of the active antipsychotic fraction. Higher doses of a strong CYP2D6 inhibitor may elevate concentrations of the Risperidone active antipsychotic fraction (e.g., paroxetine, see below).</p><p>It is expected that other CYP2D6 inhibitors, such as quinidine, may affect the plasma concentrations of Risperidone in a similar way. When concomitant paroxetine, quinidine, or another strong CYP2D6 inhibitor, especially at higher doses, is initiated or discontinued, the physician should re-evaluate the dosing of RESPAL.</p><p>CYP3A4 and/or P-gp inhibitors</p><p>Co-administration of RESPAL with a strong CYP3A4 and/or P-gp inhibitor may substantially elevate plasma concentrations of the Risperidone active antipsychotic fraction. When concomitant itraconazole or another strong CYP3A4 and/or P-gp inhibitor is initiated or discontinued, the physician should re-evaluate the dosing of RESPAL.</p><p>CYP3A4 and/or P-gp inducers</p><p>Co-administration of RESPAL with a strong CYP3A4 and/or P-gp inducer may decrease the plasma concentrations of the Risperidone active antipsychotic fraction. When concomitant carbamazepine or another strong CYP3A4 and/or P-gp inducer is initiated or discontinued, the physician should re-evaluate the dosing of RESPAL. CYP3A4 inducers exert their effect in a time-dependent manner, and may take at least 2 weeks to reach maximal effect after introduction. Conversely, on discontinuation, CYP3A4 induction may take at least 2 weeks to decline.</p><p>Highly protein-bound drugs</p><p>When RESPAL is taken together with highly protein-bound drugs, there is no clinically relevant displacement of either drug from the plasma proteins.</p><p>When using concomitant medication, the corresponding label should be consulted for information on the route of metabolism and the possible need to adjust dosage.</p><p>Paediatric population</p><p>Interaction studies have only been performed in adults. The relevance of the results from these studies in paediatric patients is unknown.<br />The combined use of psychostimulants (e.g., methylphenidate) with RESPAL in children and adolescents did not alter the pharmacokinetics and efficacy of RESPAL.</p><p>Examples</p><p>Examples of drugs that may potentially interact or that were shown not to interact with Risperidone are listed below:</p><p>Effect of other medicinal products on the pharmacokinetics of Risperidone</p><p>Antibacterials:<br />● Erythromycin, a moderate CYP3A4 inhibitor and P-gp inhibitor, does not change the pharmacokinetics of Risperidone and the active antipsychotic fraction.<br />● Rifampicin, a strong CYP3A4 inducer and a P-gp inducer, decreased the plasma concentrations of the active antipsychotic fraction.</p><p>Anticholinesterases:</p><p>● Donepezil and galantamine, both CYP2D6 and CYP3A4 substrates, do not show a clinically relevant effect on the pharmacokinetics of Risperidone and the active antipsychotic fraction.</p><p>Antiepileptics:<br />● Carbamazepine, a strong CYP3A4 inducer and a P-gp inducer, has been shown to decrease the plasma concentrations of the active antipsychotic fraction of Risperidone. Similar effects may be observed with e.g., phenytoin and phenobarbital which also induce CYP3A4 hepatic enzyme, as well as P-glycoprotein.<br />● Topiramate modestly reduced the bioavailability of Risperidone, but not that of the active antipsychotic fraction. Therefore, this interaction is unlikely to be of clinical significance.</p><p>Antifungals:<br />● Itraconazole, a strong CYP3A4 inhibitor and a P-gp inhibitor, at a dosage of 200 mg/day increased the plasma concentrations of the active antipsychotic fraction by about 70%, at Risperidone doses of 2 to 8 mg/day.<br />● Ketoconazole, a strong CYP3A4 inhibitor and a P-gp inhibitor, at a dosage of 200 mg/day increased the plasma concentrations of Risperidone and decreased the plasma concentrations of 9-hydroxy-risperidone.</p><p>Antipsychotics:</p><p>● Phenothiazines may increase the plasma concentrations of Risperidone but not those of the active antipsychotic fraction.</p><p>Antivirals:</p><p>● Protease inhibitors: No formal study data are available; however, since ritonavir is a strong CYP3A4 inhibitor and a weak CYP2D6 inhibitor, ritonavir and ritonavir-boosted protease inhibitors potentially raise concentrations of the Risperidone active antipsychotic fraction.</p><p>Beta-blockers:</p><p>● Some beta-blockers may increase the plasma concentrations of Risperidone but not those of the active antipsychotic fraction.</p><p>Calcium channel blockers:</p><p>● Verapamil, a moderate inhibitor of CYP3A4 and an inhibitor of P-gp, increases the plasma concentration of Risperidone and the active antipsychotic fraction.</p><p>Gastrointestinal drugs:</p><p>● H2-receptor antagonists: Cimetidine and ranitidine, both weak inhibitors of CYP2D6 and CYP3A4, increased the bioavailability of Risperidone, but only marginally that of the active antipsychotic fraction.</p><p>SSRIs and tricyclic antidepressants:</p><p>● Fluoxetine, a strong CYP2D6 inhibitor, increases the plasma concentration of Risperidone, but less so of the active antipsychotic fraction.<br />● Paroxetine, a strong CYP2D6 inhibitor, increases the plasma concentrations of Risperidone, but, at dosages up to 20 mg/day, less so of the active antipsychotic fraction. However, higher doses of paroxetine may elevate concentrations of the Risperidone active antipsychotic fraction.<br />● Tricyclic antidepressants may increase the plasma concentrations of Risperidone but not those of the active antipsychotic fraction. Amitriptyline does not affect the pharmacokinetics of Risperidone or the active antipsychotic fraction.<br />● Sertraline, a weak inhibitor of CYP2D6, and fluvoxamine, a weak inhibitor of CYP3A4, at dosages up to 100 mg/day are not associated with clinically significant changes in concentrations of the Risperidone active antipsychotic fraction. However, doses higher than 100 mg/day of sertraline or fluvoxamine may elevate concentrations of the Risperidone active antipsychotic fraction.</p><p>Effect of RISPERIDONE on the pharmacokinetics of other medicinal products</p><p>Antiepileptics:</p><p>● Risperidone does not show a clinically relevant effect on the pharmacokinetics of valproate or topiramate.</p><p>Antipsychotics:</p><p>● Aripiprazole, a CYP2D6 and CYP3A4 substrate: Risperidone tablets or injections did not affect the pharmacokinetics of the sum of Aripiprazole and its active metabolite, dehydroaripiprazole.</p><p>Digitalis glycosides:</p><p>● Risperidone does not show a clinically relevant effect on the pharmacokinetics of digoxin.</p><p>Lithium:</p><p>● Risperidone does not show a clinically relevant effect on the pharmacokinetics of lithium.</p><p>Concomitant use of Risperidone with furosemide<br />● See section 4.4 regarding increased mortality in elderly patients with dementia concomitantly receiving furosemide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>There are no adequate data from the use of Risperidone in pregnant women. Risperidone was not teratogenic in animal studies but other types of reproductive toxicity were seen (see section 5.3). The potential risk for humans is unknown.<br />Neonates exposed to antipsychotics (including RESPAL) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.<br />RESPAL should not be used during pregnancy unless clearly necessary. If discontinuation during pregnancy is necessary, it should not be done abruptly.</p><p>Breast-feeding</p><p>In animal studies, Risperidone and 9-hydroxy-risperidone are excreted in the milk. It has been demonstrated that Risperidone and 9-hydroxy-risperidone are also excreted in human breast milk in small quantities. There are no data available on adverse reactions in breast-feeding infants. Therefore, the advantage of breast-feeding should be weighed against the potential risks for the child.</p><p>Fertility<br />As with other drugs that antagonise dopamine D2 receptors, RISPERDAL elevates prolactin level. Hyperprolactinaemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.<br />There were no relevant effects observed in the non-clinical studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RESPAL can have minor or moderate influence on the ability to drive and use machines due to potential nervous system and visual effects (see section 4.8). Therefore, patients should be advised not to drive or operate machinery until their individual susceptibility is known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequently reported adverse drug reactions (ADRs) (incidence &ge; 10%) are: Parkinsonism, sedation/somnolence, headache, and insomnia.</p><p>The ADRs that appeared to be dose-related included parkinsonism and akathisia.</p><p>The following are all the ADRs that were reported in clinical trials and post-marketing experience with Risperidone by frequency category estimated from RESPAL clinical trials. The following terms and frequencies are applied: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000) and very rare (&lt; 1/10,000).</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="1" cellspacing="1" cellpadding="1" style="width:873px"><tbody><tr><td style="width:108px">&nbsp;</td><td style="width:139px">Adverse Drug Reaction</td><td style="width:173px">&nbsp;</td><td style="width:182px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">System Organ<br />Class</td><td style="width:139px">Frequency</td><td style="width:173px">&nbsp;</td><td style="width:182px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">&nbsp;</td><td style="width:139px">Very Common</td><td style="width:173px">Common</td><td style="width:182px">Uncommon</td><td style="width:151px">Rare</td><td style="width:123px">Very Rare</td></tr><tr><td style="width:108px">Infections and<br />infestations</td><td style="width:139px">&nbsp;</td><td style="width:173px">pneumonia, bronchitis,<br />upper respiratory tract<br />infection, sinusitis,<br />urinary tract infection,<br />ear infection, influenza</td><td style="width:182px">respiratory tract infection,<br />cystitis, eye infection,<br />tonsillitis, onychomycosis,<br />cellulitis localised infection,<br />viral infection,<br />acarodermatitis</td><td style="width:151px">infection</td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">Blood and<br />lymphatic system<br />disorders</td><td style="width:139px">&nbsp;</td><td style="width:173px">&nbsp;</td><td style="width:182px">neutropenia, white blood cell<br />count decreased,<br />thrombocytopenia, anaemia,<br />haematocrit decreased,<br />eosinophil count increased</td><td style="width:151px">agranulocytosis<sup>c</sup></td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">Immune system<br />disorders</td><td style="width:139px">&nbsp;</td><td style="width:173px">&nbsp;</td><td style="width:182px">hypersensitivity</td><td style="width:151px">anaphylactic<br />reaction<sup>c</sup></td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">Endocrine<br />disorders</td><td style="width:139px">&nbsp;</td><td style="width:173px">hyperprolactinaemia<sup>a</sup></td><td style="width:182px">&nbsp;</td><td style="width:151px">inappropriate<br />antidiuretic hormone<br />secretion, glucose<br />urine present</td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">Metabolism and<br />nutrition<br />disorders</td><td style="width:139px">&nbsp;</td><td style="width:173px">weight increased,<br />increased appetite,<br />decreased appetite</td><td style="width:182px">diabetes mellitus<sup>b</sup>,<br />hyperglycaemia, polydipsia,<br />weight decreased, anorexia,<br />blood cholesterol increased</td><td style="width:151px">water intoxication<sup>c</sup>,<br />hypoglycaemia,<br />hyperinsulinaemia<sup>c</sup>,<br />blood triglycerides<br />increased</td><td style="width:123px">diabetic<br />ketoacidosis</td></tr><tr><td style="width:108px">Psychiatric<br />disorders</td><td style="width:139px">insomnia<sup>d</sup></td><td style="width:173px">sleep disorder, agitation,<br />depression, anxiety</td><td style="width:182px">mania, confusional state,<br />libido decreased,<br />nervousness, nightmare</td><td style="width:151px">catatonia,<br />somnambulism,<br />sleep-related eating<br />disorder, blunted<br />affect, anorgasmia</td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">Nervous system<br />disorders</td><td style="width:139px">sedation/<br />somnolence,<br />parkinsonism<sup>d</sup>,<br />headache</td><td style="width:173px">akathisia<sup>d</sup>, dystonia<sup>d</sup>,<br />dizziness, dyskinesia<sup>d</sup>,<br />tremor</td><td style="width:182px">tardive dyskinesia, cerebral<br />ischaemia, unresponsive to<br />stimuli, loss of<br />consciousness, depressed<br />level of consciousness,<br />convulsion<sup>d</sup>, syncope,<br />psychomotor hyperactivity,<br />balance disorder,<br />coordination abnormal,<br />dizziness postural,<br />disturbance in attention,<br />dysarthria, dysgeusia,<br />hypoaesthesia, paraesthesia</td><td style="width:151px">neuroleptic malignant<br />syndrome,<br />cerebrovascular<br />disorder, diabetic<br />coma, head<br />titubation</td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">Eye disorders</td><td style="width:139px">&nbsp;</td><td style="width:173px">vision blurred,<br />conjunctivitis</td><td style="width:182px">photophobia, dry eye,<br />lacrimation increased, ocular<br />hyperaemia</td><td style="width:151px">glaucoma, eye<br />movement disorder,<br />eye rolling, eyelid<br />margin crusting,<br />floppy iris syndrome<br />(intraoperative)<sup>c</sup></td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">Ear and labyrinth<br />disorders</td><td style="width:139px">&nbsp;</td><td style="width:173px">&nbsp;</td><td style="width:182px">vertigo, tinnitus, ear pain</td><td style="width:151px">&nbsp;</td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">Cardiac disorders</td><td style="width:139px">&nbsp;</td><td style="width:173px">tachycardia</td><td style="width:182px">atrial fibrillation,<br />atrioventricular block,<br />conduction disorder,<br />electrocardiogram QT<br />prolonged, bradycardia,<br />electrocardiogram abnormal,<br />palpitations</td><td style="width:151px">sinus arrhythmia</td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">Vascular<br />disorders</td><td style="width:139px">&nbsp;</td><td style="width:173px">hypertension</td><td style="width:182px">hypotension, orthostatic<br />hypotension, flushing</td><td style="width:151px">pulmonary embolism,<br />venous thrombosis</td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">Respiratory,<br />thoracic and<br />mediastinal<br />disorders</td><td style="width:139px">&nbsp;</td><td style="width:173px">dyspnoea,<br />pharyngolaryngeal pain,<br />cough, epistaxis, nasal<br />congestion</td><td style="width:182px">pneumonia aspiration,<br />pulmonary congestion,<br />respiratory tract congestion,<br />rales, wheezing, dysphonia,<br />respiratory disorder</td><td style="width:151px">sleep apnoea<br />syndrome,<br />hyperventilation</td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">Gastrointestinal<br />disorders</td><td style="width:139px">&nbsp;</td><td style="width:173px">abdominal pain,<br />abdominal discomfort,<br />vomiting, nausea,<br />constipation, diarrhoea,<br />dyspepsia, dry mouth,<br />toothache</td><td style="width:182px">faecal incontinence,<br />faecaloma, gastroenteritis,<br />dysphagia, flatulence</td><td style="width:151px">pancreatitis,<br />intestinal obstruction,<br />swollen tongue,<br />cheilitis</td><td style="width:123px">ileus</td></tr><tr><td style="width:108px">Skin and<br />subcutaneous<br />tissue disorders</td><td style="width:139px">&nbsp;</td><td style="width:173px">rash, erythema</td><td style="width:182px">urticaria, pruritus, alopecia,<br />hyperkeratosis, eczema, dry<br />skin, skin discolouration,<br />acne, seborrhoeic dermatitis,<br />skin disorder, skin lesion</td><td style="width:151px">drug eruption,<br />dandruff</td><td style="width:123px">angioedema</td></tr><tr><td style="width:108px">Musculoskeletal<br />and connective<br />tissue disorders</td><td style="width:139px">&nbsp;</td><td style="width:173px">muscle spasms,<br />musculoskeletal pain,<br />back pain, arthralgia</td><td style="width:182px">blood creatine<br />phosphokinase increased,<br />posture abnormal, joint<br />stiffness, joint swelling<br />muscular weakness, neck<br />pain</td><td style="width:151px">rhabdomyolysis</td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">Renal and urinary<br />disorders</td><td style="width:139px">&nbsp;</td><td style="width:173px">urinary incontinence</td><td style="width:182px">pollakiuria, urinary retention,<br />dysuria</td><td style="width:151px">&nbsp;</td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">Pregnancy,<br />puerperium, and<br />neonatal<br />conditions</td><td style="width:139px">&nbsp;</td><td style="width:173px">&nbsp;</td><td style="width:182px">&nbsp;</td><td style="width:151px">drug withdrawal<br />syndrome neonatal<sup>c</sup></td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">Reproductive<br />system and<br />breast disorders</td><td style="width:139px">&nbsp;</td><td style="width:173px">&nbsp;</td><td style="width:182px">erectile dysfunction,<br />ejaculation disorder,<br />amenorrhoea, menstrual<br />disorder<sup>d</sup>, gynaecomastia,<br />galactorrhoea, sexual<br />dysfunction, breast pain,<br />breast discomfort, vaginal<br />discharge</td><td style="width:151px">priapism<sup>c</sup>,<br />menstruation<br />delayed, breast<br />engorgement, breast<br />enlargement, breast<br />discharge</td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">General disorders<br />and<br />administration<br />site conditions</td><td style="width:139px">&nbsp;</td><td style="width:173px">oedema<sup>d</sup>, pyrexia, chest<br />pain, asthenia, fatigue,<br />pain</td><td style="width:182px">face oedema, chills, body<br />temperature increased, gait<br />abnormal, thirst, chest<br />discomfort, malaise, feeling<br />abnormal, discomfort</td><td style="width:151px">hypothermia, body<br />temperature<br />decreased,<br />peripheral coldness,<br />drug withdrawal<br />syndrome,<br />induration<sup>c</sup></td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">Hepatobiliary<br />disorders</td><td style="width:139px">&nbsp;</td><td style="width:173px">&nbsp;</td><td style="width:182px">transaminases increased,<br />gamma-glutamyltransferase<br />increased, hepatic enzyme<br />increased</td><td style="width:151px">jaundice</td><td style="width:123px">&nbsp;</td></tr><tr><td style="width:108px">Injury, poisoning<br />and procedural<br />complications</td><td style="width:139px">&nbsp;</td><td style="width:173px">fall</td><td style="width:182px">procedural pain</td><td style="width:151px">&nbsp;</td><td style="width:123px">&nbsp;</td></tr></tbody></table><p>a Hyperprolactinaemia can in some cases lead to gynaecomastia, menstrual disturbances, amenorrhoea, anovulation,<br />galactorrhoea, fertility disorder, decreased libido, erectile dysfunction.</p><p>b In placebo-controlled trials diabetes mellitus was reported in 0.18% in Risperidone-treated subjects compared to a rate of 0.11%<br />in placebo group. Overall incidence from all clinical trials was 0.43% in all Risperidone-treated subjects.</p><p>c Not observed in RESPAL clinical studies but observed in post-marketing environment with Risperidone.</p><p>d Extrapyramidal disorder may occur: Parkinsonism (salivary hypersecretion, musculoskeletal stiffness, parkinsonism, drooling,<br />cogwheel rigidity, bradykinesia, hypokinesia, masked facies, muscle tightness, akinesia, nuchal rigidity, muscle rigidity,<br />parkinsonian gait, and glabellar reflex abnormal, parkinsonian rest tremor), akathisia (akathisia, restlessness, hyperkinesia, and<br />restless leg syndrome), tremor, dyskinesia (dyskinesia, muscle twitching, choreoathetosis, athetosis, and myoclonus), dystonia.</p><p>Dystonia includes dystonia, hypertonia, torticollis, muscle contractions involuntary, muscle contracture, blepharospasm,<br />oculogyration, tongue paralysis, facial spasm, laryngospasm, myotonia, opisthotonus, oropharyngeal spasm, pleurothotonus,<br />tongue spasm, and trismus. It should be noted that a broader spectrum of symptoms are included, that do not necessarily have<br />an extrapyramidal origin. Insomnia includes initial insomnia, middle insomnia. Convulsion includes grand mal convulsion.</p><p>Menstrual disorder includes menstruation irregular, oligomenorrhoea. Oedema includes generalised oedema, oedema<br />peripheral, pitting oedema.</p><p>Undesirable effects noted with paliperidone formulations<br />Paliperidone is the active metabolite of Risperidone, therefore, the adverse reaction profiles of these compounds (including both the oral and injectable formulations) are relevant to one another. In addition to the above adverse reactions, the following adverse reaction has been noted with the use of paliperidone products and can be expected to occur with RESPAL.</p><p>Cardiac disorders<br />Postural orthostatic tachycardia syndrome<br />Class effects<br />As with other antipsychotics, very rare cases of QT prolongation have been reported post-marketing with Risperidone. Other class-related cardiac effects reported with antipsychotics which prolong QT interval include ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, sudden death, cardiac arrest and Torsades de Pointes.</p><p>Venous thromboembolism<br />Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis, have been reported with antipsychotic drugs (frequency unknown).</p><p>Weight gain<br />The proportions of RESPAL and placebo-treated adult patients with schizophrenia meeting a weight gain criterion of &ge; 7% of body weight were compared in a pool of 6- to 8-week, placebo-controlled trials, revealing a statistically significantly greater incidence of weight gain for RESPAL (18%) compared to placebo (9%). In a pool of placebo-controlled 3-week studies in adult patients with acute mania, the incidence of weight increase of &ge; 7% at endpoint was comparable in the RESPAL (2.5%) and placebo (2.4%) groups, and was slightly higher in the active-control group (3.5%).</p><p>In a population of children and adolescents with conduct and other disruptive behaviour disorders, in long-term studies, weight increased by a mean of 7.3 kg after 12 months of treatment. The expected weight gain for normal children between 5-12 years of age is 3 to 5 kg per year. From 12-16 years of age, this magnitude of gaining 3 to 5 kg per year is maintained for girls, while boys gain approximately 5 kg per year.</p><p>Additional information on special populations</p><p>Adverse drug reactions that were reported with higher incidence in elderly patients with dementia or paediatric patients than in adult populations are described below:</p><p>Elderly patients with dementia</p><p>Transient ischaemic attack and cerebrovascular accident were ADRs reported in clinical trials with a frequency of 1.4% and 1.5%, respectively, in elderly patients with dementia. In addition, the following ADRs were reported with a frequency &ge; 5% in elderly patients with dementia and with at least twice the frequency seen in other adult populations: urinary tract infection, peripheral oedema, lethargy, and cough.</p><p>Paediatric population</p><p>In general, type of adverse reactions in children is expected to be similar to those observed in adults.<br />The following ADRs were reported with a frequency &ge; 5% in paediatric patients (5 to 17 years) and with at least twice the frequency seen in clinical trials in adults: somnolence/sedation, fatigue, headache, increased appetite, vomiting, upper respiratory tract infection, nasal congestion, abdominal pain, dizziness, cough, pyrexia, tremor, diarrhoea, and enuresis.</p><p>The effect of long-term Risperidone treatment on sexual maturation and height has not been adequately studied (see section 4.4, subsection &ldquo;Paediatric population&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms</p><p>In general, reported signs and symptoms have been those resulting from an exaggeration of the known pharmacological effects of Risperidone. These include drowsiness and sedation, tachycardia and hypotension, and extrapyramidal symptoms. In overdose, QT prolongation and convulsions have been reported. Torsade de Pointes has been reported in association with combined overdose of RESPAL and paroxetine.</p><p>In case of acute overdose, the possibility of multiple drug involvement should be considered.</p><p>Treatment</p><p>Establish and maintain a clear airway and ensure adequate oxygenation and ventilation. Administration of activated charcoal together with a laxative should be considered only when drug intake was less than one hour before. Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias.</p><p>There is no specific antidote to RESPAL. Therefore, appropriate supportive measures should be instituted. Hypotension and circulatory collapse should be treated with appropriate measures such as intravenous fluids and/or sympathomimetic agents. In case of severe extrapyramidal symptoms, an anticholinergic medicinal product should be administered. Close medical supervision and monitoring should continue until the patient recovers.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other antipsychotics, ATC code: N05AX08.</p><p>Mechanism of action</p><p>Risperidone is a selective monoaminergic antagonist with unique properties. It has a high affinity for serotoninergic 5-HT2 and dopaminergic D2 receptors. Risperidone binds also to alpha1-adrenergic receptors, and, with lower affinity, to H1-histaminergic and alpha2-adrenergic receptors. Risperidone has no affinity for cholinergic receptors. Although Risperidone is a potent D2 antagonist, which is considered to improve the positive symptoms of schizophrenia, it causes less depression of motor activity and induction of catalepsy than classical antipsychotics. Balanced central serotonin and dopamine antagonism may reduce extrapyramidal side effect liability and extend the therapeutic activity to the negative and affective symptoms of schizophrenia.</p><p>Pharmacodynamic effects</p><p>Clinical efficacy</p><p>Schizophrenia</p><p>The efficacy of Risperidone in the short-term treatment of schizophrenia was established in four studies, 4 to 8 weeks in duration, which enrolled over 2,500 patients who met DSM-IV criteria for schizophrenia. In a 6-week, placebo-controlled trial involving titration of Risperidone in doses up to 10 mg/day administered twice daily, Risperidone was superior to placebo on the Brief Psychiatric Rating Scale (BPRS) total score. In an 8-week, placebo-controlled trial involving four fixed doses of Risperidone (2, 6, 10, and 16 mg/day, administered twice daily), all four Risperidone groups were superior to placebo on the Positive and Negative Syndrome Scale (PANSS) total score. In an 8-week, dose comparison trial involving five fixed doses of Risperidone (1, 4, 8, 12, and 16 mg/day administered twice daily), the 4, 8, and 16 mg/day Risperidone dose groups were superior to the 1 mg Risperidone dose group on PANSS total score. In a 4-week, placebo-controlled dose comparison trial involving two fixed doses of Risperidone (4 and 8 mg/day administered once daily), both Risperidone dose groups were superior to placebo on several PANSS measures, including total PANSS and a response measure (&gt; 20% reduction in PANSS total score). In a longer-term trial, adult outpatients predominantly meeting DSM-IV criteria for schizophrenia and who had been clinically stable for at least 4 weeks on an antipsychotic medicinal product were randomised to Risperidone 2 to 8 mg/day or to haloperidol for 1 to 2 years of observation for relapse. Patients receiving Risperidone experienced a significantly longer time to relapse over this time period compared to those receiving haloperidol.</p><p>Manic episodes in bipolar disorder</p><p>The efficacy of Risperidone monotherapy in the acute treatment of manic episodes associated with bipolar I disorder was demonstrated in three double-blind, placebo-controlled monotherapy studies in approximately 820 patients who had bipolar I disorder, based on DSM-IV criteria. In the three studies, Risperidone 1 to 6 mg/day (starting dose 3 mg in two studies and 2 mg in one study) was shown to be significantly superior to placebo on the pre-specified primary endpoint, i.e., the change from baseline in total Young Mania Rating Scale (YMRS) score at week 3. Secondary efficacy outcomes were generally consistent with the primary outcome. The percentage of patients with a decrease of &ge; 50% in total YMRS score from baseline to the 3-week endpoint was significantly higher for Risperidone than for placebo.</p><p>One of the three studies included a haloperidol arm and a 9-week double-blind maintenance phase.</p><p>Efficacy was maintained throughout the 9-week maintenance treatment period. Change from baseline in total YMRS showed continued improvement and was comparable between Risperidone and haloperidol at week 12.</p><p>The efficacy of Risperidone in addition to mood stabilisers in the treatment of acute mania was demonstrated in one of two 3-week double-blind studies in approximately 300 patients who met the DSM-IV criteria for bipolar I disorder. In one 3-week study, Risperidone 1 to 6 mg/day starting at 2 mg/day in addition to lithium or valproate was superior to lithium or valproate alone on the pre-specified primary endpoint, i.e., the change from baseline in YMRS total score at week 3. In a second 3-week study, Risperidone 1 to 6 mg/day starting at 2 mg/day, combined with lithium, valproate, or carbamazepine was&nbsp;not superior to lithium, valproate, or carbamazepine alone in the reduction of YMRS total score. A possible explanation for the failure of this study was induction of Risperidone and 9-hydroxy-risperidone clearance by carbamazepine, leading to subtherapeutic levels of Risperidone and 9-hydroxy-risperidone.</p><p>When the carbamazepine group was excluded in a post-hoc analysis, Risperidone combined with lithium or valproate was superior to lithium or valproate alone in the reduction of YMRS total score.</p><p>Persistent aggression in dementia</p><p>The efficacy of Risperidone in the treatment of Behavioural and Psychological Symptoms of Dementia (BPSD), which includes behavioural disturbances, such as aggressiveness, agitation, psychosis, activity, and affective disturbances was demonstrated in three double-blind, placebo-controlled studies in 1,150 elderly patients with moderate to severe dementia. One study included fixed Risperidone doses of 0.5, 1, and 2 mg/day. Two flexible-dose studies included Risperidone dose groups in the range of 0.5 to 4 mg/day and 0.5 to 2 mg/day, respectively. Risperidone showed statistically significant and clinically important effectiveness in treating aggression and less consistently in treating agitation and psychosis in elderly dementia patients (as measured by the Behavioural Pathology in Alzheimer&#39;s Disease Rating Scale [BEHAVE-AD] and the Cohen-Mansfield Agitation Inventory [CMAI]). The treatment effect of Risperidone was independent of Mini-Mental State Examination (MMSE) score (and consequently of the severity of dementia); of sedative properties of Risperidone; of the presence or absence of psychosis; and of the type of dementia, Alzheimer&#39;s, vascular, or mixed (see also section 4.4).</p><p>Paediatric population</p><p>Conduct disorder</p><p>The efficacy of Risperidone in the short-term treatment of disruptive behaviours was demonstrated in two double-blind placebo-controlled studies in approximately 240 patients 5 to 12 years of age with a DSM-IV diagnosis of disruptive behaviour disorders (DBD) and borderline intellectual functioning or mild or moderate mental retardation/learning disorder. In the two studies, Risperidone 0.02 to 0.06 mg/kg/day was significantly superior to placebo on the pre-specified primary endpoint, i.e., the change from baseline in the Conduct Problem subscale of the Nisonger-Child Behaviour Rating Form (N-CBRF) at week 6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RISPERIDONE orodispersible tablets and oral solution are bioequivalent to RISPERIDONE tablets.<br />Risperidone is metabolised to 9-hydroxy-risperidone, which has a similar pharmacological activity to RISPERIDONE (see Biotransformation and Elimination).</p><p>Absorption</p><p>Risperidone is completely absorbed after oral administration, reaching peak plasma concentrations within 1 to 2 hours. The absolute oral bioavailability of Risperidone is 70% (CV=25%). The relative oral bioavailability of Risperidone from a tablet is 94% (CV=10%) compared with a solution. The absorption is not affected by food and thus Risperidone can be given with or without meals. Steady-state of Risperidone is reached within 1 day in most patients. Steady-state of 9-hydroxy- isperidone is reached within 4-5 days of dosing.</p><p>Distribution</p><p>Risperidone is rapidly distributed. The volume of distribution is 1-2 l/kg. In plasma, Risperidone is bound to albumin and alpha1-acid glycoprotein. The plasma protein binding of Risperidone is 90%, that of 9- hydroxy-risperidone is 77%.</p><p>Biotransformation and elimination</p><p>Risperidone is metabolised by CYP2D6 to 9-hydroxy-risperidone, which has a similar pharmacological activity as Risperidone. Risperidone plus 9-hydroxy-risperidone form the active antipsychotic fraction. CYP2D6 is subject to genetic polymorphism. Extensive CYP2D6 metabolisers convert Risperidone rapidly into 9-hydroxy-risperidone, whereas poor CYP2D6 metabolisers convert it much more slowly. Although extensive metabolisers have lower Risperidone and higher 9- hydroxy-risperidone concentrations than poor metabolisers, the pharmacokinetics of Risperidone and 9-hydroxy-risperidone combined (i.e., the active antipsychotic fraction), after single and multiple doses, are similar in extensive and poor metabolisers of CYP2D6.</p><p>Another metabolic pathway of Risperidone is N-dealkylation. In vitro studies in human liver microsomes showed that Risperidone at clinically relevant concentration does not substantially inhibit the metabolism of medicines metabolised by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. One week after administration, 70% of the dose is excreted in the urine and 14% in the faeces. In urine, Risperidone plus 9-hydroxy-risperidone represent 35-45% of the dose. The remainder is inactive metabolites. After oral administration to psychotic patients, Risperidone is eliminated with a half-life of about 3 hours. The elimination half-life of 9- hydroxy-risperidone and of the active antipsychotic fraction is 24 hours.</p><p>Linearity/non-linearity</p><p>Risperidone plasma concentrations are dose-proportional within the therapeutic dose-range.</p><p>Elderly, hepatic and renal impairment</p><p>A single-dose PK-study with oral Risperidone showed on average a 43% higher active antipsychotic fraction plasma concentrations, a 38% longer half-life and a reduced clearance of the active antipsychotic fraction by 30% in the elderly.</p><p>In adults with moderate renal disease the clearance of the active moiety was ~48% of the clearance in young healthy adults. In adults with severe renal disease the clearance of the active moiety was ~31% of the clearance in young healthy adults. The half-life of the active moiety was 16.7 h in young adults, 24.9 h in adults with moderate renal disease (or ~1.5 times as long as in young adults), and 28.8 h in those with severe renal disease (or ~1.7 times as long as in young adults). Risperidone plasma concentrations were normal in patients with liver insufficiency, but the mean free fraction of Risperidone in plasma was increased by 37.1%.</p><p>The oral clearance and the elimination half-life of Risperidone and of the active moiety in adults with moderate and severe liver impairment were not significantly different from those parameters in young healthy adults.</p><p>Paediatric population</p><p>The pharmacokinetics of Risperidone, 9-hydroxy-risperidone and the active antipsychotic fraction in children are similar to those in adults.</p><p>Gender, race and smoking habits</p><p>A population pharmacokinetic analysis revealed no apparent effect of gender, race or smoking habits on the pharmacokinetics of Risperidone or the active antipsychotic fraction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In (sub)chronic toxicity studies, in which dosing was started in sexually immature rats and dogs, dosedependent effects were present in male and female genital tract and mammary gland. These effects were related to the increased serum prolactin levels, resulting from the dopamine D2 receptor blocking activity of Risperidone. In addition, tissue culture studies suggest that cell growth in human breast tumours may be stimulated by prolactin. Risperidone was not teratogenic in rat and rabbit. In rat reproduction studies with Risperidone, adverse effects were seen on mating behaviour of the parents, and on the birth weight and survival of the offspring. In rats, intrauterine exposure to Risperidone was associated with cognitive deficits in adulthood. Other dopamine antagonists, when administered to pregnant animals, have caused negative effects on learning and motor development in the offspring. In a toxicity study in juvenile rats, increased pup mortality and a delay in physical development was observed. In a 40-week study with juvenile dogs, sexual maturation was delayed. Based on AUC, long bone growth was not affected in dogs at 3.6-times the maximum human exposure in adolescents (1.5 mg/day); while effects on long bones and sexual maturation were observed at 15 times the maximum human exposure in adolescents.</p><p>Risperidone was not genotoxic in a battery of tests. In oral carcinogenicity studies of Risperidone in rats and mice, increases in pituitary gland adenomas (mouse), endocrine pancreas adenomas (rat), and mammary gland adenomas (both species) were seen. These tumours can be related to prolonged dopamine D2 antagonism and hyperprolactinaemia. The relevance of these tumour findings in rodents in terms of human risk is unknown. In vitro and in vivo, animal models show that at high doses Risperidone may cause QT interval prolongation, which has been associated with a theoretically increased risk of Torsade de Pointes in patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate<br />Microcrystalline cellulose<br />Sodium lauryl sulphate<br />Maize starch<br />Colloidal silicon dioxide<br />Magnesium stearate<br />HPMC 5 CP<br />Glycerin<br />PEG<br />Talc<br />Sunset yellow dye for {Respal 2mg}<br />FD&amp;C blue # 2 dye {for Respal 4mg}<br />Quiniline yellow {for Respal 4mg}</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Primary packaging material<br />PVC/PE/PVDC Clear, Triplex - Aluminum blister pack.<br />Secondary packaging material<br />Printed cardboard case containing the blisters and the package insert.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jordan Sweden Medical and Sterilization
Joswe-medical
P.O. Box 851831 Amman 11185 Jordan
E-mail: info@joswe.com
www.joswe.com
Tel: +962 6 5859765, +962 6 5728327
Fax: +962 6 5814526, +962 6 5728326
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2023.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>